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ABSTRACT 	 The presence of AML1-ETO (RUNX1-CBF2T1), a fusion oncoprotein resulting 
from a t(8;21) chromosomal translocation, is a necessary but insufficient event in the 
development of a subset of acute myeloid leukemias (AML). Although AML1-ETO is 
able to block differentiation and immortalize hematopoietic stem cells, other contributory 
events are required for cell proliferation and leukemogenesis, suggesting that specific 
tumor suppressor genes may counteract the leukemic potential of AML1-ETO.  	 In studying del(9q), one of the most common concomitant chromosomal 
abnormalities with t(8;21), we identified the loss of TLE4 as a key cooperating event in 
the development of AML1-ETO AML, leading to increased cell proliferation, blocked 
apoptosis and differentiation, as well as cytarabine resistance in leukemic cells. This 
suggested TLE4 functions as a tumor suppressor gene in AML.We found these effects are 
mediated by the loss of TLE4 regulation of a COX-Wnt inflammatory axis. These effects 
were consequently reversible by Wnt signaling and cyclooxygenase inhibition, pointing 
		 viii 
towards anti-inflammatory agents as potentially new therapeutic and adjuvant strategies 
for AML.  	 While studies in Drosophila implicate TLE/Groucho as a key mediator of various 
signaling pathways, including receptor tyrosine kinase/Ras/MAPK, Notch, Myc, and Wnt 
pathways, there is surprisingly little known about the role of TLE in mammalian 
development. Using a Tle4 knockout (T4KO) mouse, we identified previously unknown 
roles for Tle4 in regulating vertebrate mammalian hematopoietic and bone development. 
T4KO mice manifest leukocytopenia and defective hematopoietic stem cell populations. 
Using serial transplantation and stromal co-culture, we find that these hematopoietic 
deficiencies arise due to both intrinsic dysfunction of hematopoietic stem cells as well as 
defective extrinsic regulation of hematopoiesis by the stem cell niche. Additionally, 
T4KO mice are severely runted and exhibit markedly decreased bone mineralization 
concomitant with defective osteoblast function and decreased mineral apposition rates.  	 Many of the pathways regulated by TLE are aberrant in cancer, which has led to 
increasing studies connecting TLE with various malignancies, including synovial cell 
sarcoma and glioblastoma. Our findings have great implications for current 
understanding of TLE function in not only cancer, but also bone and hematopoietic 
development. 
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CHAPTER ONE: INTRODUCTION 
Leukemia arises from aberrant hematopoiesis 
Leukemia background 
 Leukemia is a cancer of white blood cells that involves bone marrow and the 
peripheral blood. The earliest reliable records of leukemia originate from the work done 
by Bennett and Virchow in 1845 and 18471. In his work, Bennett describes leukemia as a 
“suppuration of the blood” where he noted increased numbers of white blood cells in the 
absence of inflammation2. First coined by Virchow to describe a similar observation in 
another patient, the term leukemia originates from the German word Leukämie, first 
coined by Virchow combining the Greek words for white, “leukos,” and blood, “haima.”3 
Today, the scientific community understands leukemia pathogenesis to originate from the 
dysregulation of normal hematopoiesis, the process through which blood cells develop. 
These events are often secondary to mutations and chromosomal abnormalities that 
impair the function of key transcription factors and hematopoietic regulators. In 
leukemia, irregularities in normal hematopoiesis manifest as blocked maturation and 
abnormal proliferation of immature blood cells at specific points of development.  
Hematopoiesis and regulators of blood development 
 Hematopoiesis starts with a hematopoietic stem cell (HSC), a pluripotent cell that 
has the capacity to self-renew and differentiate to give rise to all types of blood cells in 
the hematopoietic compartment. Each stage of hematopoiesis involves various triggers to 
guide HSC commitment towards generating different kinds of early immature cells with 
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varying differentiation capacities, such as long-term HSCs (LT-HSC), short-term HSCs 
(ST-HSC), and various types of progenitors. While the exact identification of the human 
hematopoietic stem cell remains under contention, the field has derived much of the 
current understanding of HSCs by studying mouse hematopoiesis. It is now understood 
that LT-HSCs retain self-renewal and pluripotency that is carefully maintained by various 
signaling pathways and transcription factors, including Runx1, Bmi-1, and Gata-2 among 
others4. Upon differentiation, LT-HSCs give rise to ST-HSCs and other multipotent 
progenitors that are committed to broad tracks of differentiation, the most expansive 
distinctions of which are the myeloid and lymphoid lineages. Upon commitment to the 
myeloid lineage, HSCs give rise to the common myeloid progenitor (CMP), which 
produce other immature early myeloid progenitors that eventually differentiate into 
megakaryocytes, erythrocytes, eosinophils, basophils, monocytes, and neutrophils. On the 
other hand, HSCs committed to the lymphoid lineage give rise to common lymphoid 
progenitors (CLP) that develop into lymphocytes, such as B and T cells. The regulation 
of this process involves the concerted efforts of various factors both within and outside 
the HSC, often referred to as HSC intrinsic and extrinsic factors, respectively.  
 Using various animal and in vitro models, the scientific community has identified 
several transcription factors that play a critical role in HSC intrinsic regulation of 
hematopoiesis and differentiation. The mutation or aberrant function of many of these 
genes has been implicated in various types of leukemias and hematologic malignancies. 
For example, the absence of Runx1 in mice led to embryonic lethality that is attributed to 
absence of bone and hematopoietic development5. Mll, another transcription factor, is 
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thought to regulate expression of other downstream mediators of hematopoiesis and be 
critical to the normal generation of HSCs6. Moreover, it is now understood that different 
transcription factors play context-specific roles in hematopoiesis depending on the stage 
of differentiation and lineage commitment. Within the myeloid lineage, Gata-1, Pu.1, and 
members of the Cebp family of transcription factors are known to regulate granulocytic-
monocytic progenitor differentiation into eosinophils, neutrophils, and monocytes7. Gata-
1 is also involved in megakaryocyte-erythroblast progenitor differentiation into mature 
red blood cells, demonstrating the context-specificity of transcription factor regulation of 
hematopoiesis at various points of differentiation. While many of the transcription factors 
identified as hematopoietic regulators involve direct DNA binding and transcriptional 
regulation, various signaling pathways have also been implicated as principal regulators 
of hematopoiesis. Models of aberrant Notch signaling via loss-of-function or knockout of 
Notch1 revealed its importance in mediating HSC generation and lymphocyte 
development4,8,9. Other studies have revealed that Wnt signaling is a regulator of 
hematopoietic stem cell viability and differentiation10,11. While its presence promotes 
HSC induction, mouse models of gain-of-function mutant β-catenin revealed constitutive 
Wnt signaling activation leads to decreased HSC differentiation, indicating a need to 
precisely regulate this pathway12. Zebrafish and mouse models of hematopoiesis have 
revealed the role of cyclooxygenase (COX) and prostaglandin, principal mediators of 
inflammation, in HSC induction through a Wnt-signaling dependent mechanism7,13. 
Interestingly, COX-mediated inflammation has been implicated as a driver for leukemic 
cell viability, further illustrating the importance of understanding the role of various HSC 
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intrinsic mediators of hematopoiesis to elucidate their potential significance in 
leukemogenesis14.   
While hematopoiesis first starts in the yolk sac, aorta-gonad-mesonephros region, 
and fetal liver in utero, HSC maintenance and differentiation occurs in various 
hematopoietic organs throughout life, such as the bone marrow, spleen, and thymus4. In 
all sites of hematopoiesis, HSCs are believed to reside in microenvironments, or niches, 
that combine various HSC extrinsic factors to create a hospitable and nurturing 
environment that promotes HSC viability and development. This niche, first described by 
Schofield in 1978, has become a central focus in the scientific community to understand 
how HSCs develop and function15. While there are indeed many kinds of HSC niches as 
sites of hematopoiesis change throughout life, most of the field’s current understanding 
of the HSC niche originates from work done in the adult mouse bone marrow. Previous 
work has shown evidence of endothelial and sinusoidal cell regulation of hematopoiesis 
through soluble factors and interactions dependent on close proximity to HSCs16,17. 
Osteoblasts, a principal player in bone development, were also found to exert a role in 
hematopoiesis through studies that found increased osteoblast number due to parathyroid 
hormone receptor activity is associated with increased HSC populations18. Osteoblasts 
communicate with HSCs through various secreted moieties as well as direct receptor-
ligand interactions to support HSC adhesion and residence in the niche, including 
interactions between N-cadherin/β-catenin, and osteopontin/β1integrin19. Conversely, 
osteoblast ablation in mice resulted in the loss of various hematopoietic progenitors20. In 
addition to bone and vascular cells, the putative HSC niche in the bone marrow consists 
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of mesenchymal stromal cells and sympathetic neurons21. Studies have shown 
localization of HSCs near mesenchymal stromal cells with high expression of CXC 
chemokine ligand 12 (CXCL12), whose selective deletion led to decreased numbers of 
HSCs22. This was further supported by the observation that ablation of CXCL12 receptor, 
CXCR4, caused decreased HSC populations in the bone marrow and their increased 
sensitivity to chemotherapeutics23. Adrenergic nerve fibers have also been found in close 
proximity to HSCs and are now thought to contribute to bone marrow stromal cell 
maintenance, exerting an indirect role on HSC maintenance24. Continued efforts towards 
understanding the architecture and constituents of the HSC niche will provide greater 
insight into understanding how HSC extrinsic factors interplay with HSC intrinsic 
regulation of hematopoiesis and elucidate new therapeutic strategies to target 
leukemogenic aberrations in hematopoiesis.  
Thus, regulation of bone metabolism and development are critical in ensuring 
bone marrow health and normal hematopoiesis. Normal bone development depends on a 
balance between bone formation and bone resorption. These two processes are mediated 
by osteoblasts and osteoclasts, respectively. The imbalance of these two forces towards 
one side results in various bone pathologies, including osteopetrosis and osteoporosis25. 
Osteoblasts are derived from mesenchymal cells that are triggered by Wnt signaling 
towards osteoblastic differentiation26. Various factors, including Wnt signaling and 
Runx2, have been found to play roles in not only normal osteoblast function but also 
maturation and viability. The loss of Runx2, a known interaction partner of Tle co-
repressors, in mice results in complete lack of skeletal development thought to be 
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secondary to aberrant osteoblast differentiation25. Additionally, previous studies have 
shown the ability to induce osteoblastic differentiation of mouse stromal cells by 
induction of Runx2 expression27. Other key regulators of osteoblast differentiation 
include osteoproteregin, osterix, and alkaline phosphatase, and osteopontin. These factors 
are expressed at different stages of osteoblast differentiation and regulate osteoblast 
precursor fate decisions, bone metabolism, and osteoclast induction25. As they mature, 
functional osteoblasts primarily serve three functions: production of osteoid, regulation of 
bone mineralization, and manage osteoclast induction. Various assays are used to assess 
normal osteoblast function and development, including dynamic bone formation 
parameters, mineral apposition rates, bone histology, and detection of key osteoblast 
genes, such as osteocalcin. Osteocalcin is one of the main components of ground 
substance that, together with Type 1 collagen, constitute the bone matrix26,28,29. Thus, 
osteoblasts serve as an intersection that draws an intimate connection between bone 
formation and hematopoiesis. 
Genetic basis of leukemia 
In leukemia, dysregulation of hematopoiesis causes abnormal proliferation of 
blood cells at specific stages of maturity related to the point of blocked or abnormal 
differentiation. This allows for the categorization of leukemia into four main groups: 
acute myeloid, acute lymphoid, chronic myeloid, and chronic lymphoid. The 
differentiation of acute versus chronic types of leukemia refers to the proliferation of 
immature non-functioning blasts or mature blood cells, respectively. Myeloid leukemias 
involve blood cells of the myeloid lineage, which results in the development of 
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eosinophils, monocytes, neutrophils, and granulocytes. On the other hand, lymphoblastic 
or lymphoid leukemias involve the proliferation of lymphoid progenitors or mature 
lymphocytes. Each category of leukemia presents with slightly different clinical 
presentations that are associated with different prognoses. In acute leukemias, a 
differentiation block prohibits the normal development of functional mature blood cells 
downstream. Moreover, the increased proliferation of immature blasts crowd out the bone 
marrow, leading to decreased production of other lineages and types of blood cells. These 
combined factors lead to a rapid deterioration of the hematopoietic compartment and 
contribute to decreased survival rates compared to chronic leukemia patients. Due to the 
presence of functioning mature blood cells, chronic leukemias are associated with higher 
survival rates and a slower disease progression. However, chronic leukemias have the 
potential to enter a more rapid, proliferative disease state that manifests itself in a “blast 
crisis” or an acute leukemia-like presentation. While our understanding of leukemia 
development has significantly advanced since the 19th century, leukemia remains a 
deadly disease. Despite many advances leading to increased rates of remission, leukemia 
continues to be the sixth leading cause of cancer-related deaths in the United States and 
has an overall five-year survival rate of only 20%30.  
Given its significant public health impact, increasing efforts have been made to 
understand the molecular basis of leukemia development. The most seminal example of 
this effort is the revelation of the molecular pathophysiology of chronic myelogenous 
leukemia (CML) due to the Philadelphia chromosome. The Philadelphia chromosome, 
resultant from a t(9;22) translocation, creates a constitutively active tyrosine kinase that 
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triggers various pathways involved in hematopoietic progenitor growth such as RAS and 
JAK-STAT signaling31,32. CML manifests in massive proliferation of immature 
granulocytes that progress with differentiation causing neutrophilia, eosinophilia, 
basophilia, monocytosis, thrombocytosis, and anemia. It is now understood that many 
different mutations and chromosomal abnormalities may contribute to leukemia 
development by interfering with normal hematopoietic regulation. Within the HSC, 
studies have revealed that specific translocations, such as t(8;21) and t(9;11), lead to the 
formation of chimeric oncogenes, AML1-ETO and MLL-AF9 respectively, that interfere 
with normal function of key hematopoietic regulators such as RUNX1 and MLL33,34. The 
presence of these oncogenes in HSCs confers increases self-renewability and transfer of 
disease to a healthy recipient, suggesting that their presence allows for hematopoietic 
cells to propagate and establish leukemia35,36. The resultant chimeric oncoproteins disrupt 
the normal function of hematopoiesis regulators and the homeostasis of key signaling 
pathways, including Wnt signaling37,38. Outside of cytogenetic abnormalities, a variety of 
mutations in various tumor suppressors and tyrosine kinases, such as Rb, p53, c-Kit, and 
Flt3, have been found in leukemia5,35,39-41.  
Aberrant regulation of the bone marrow niche also appears to play a role in 
leukemia development. Interestingly, constitutive expression of β-catenin in osteoblasts 
via the Colα1 promoter resulted in myeloproliferative disorders in mice42. Additionally, 
deletion of tumor suppressor Rb in Mx1-expressing stromal cells resulted in 
myelodysplastic syndrome43. The relationship between the bone marrow environment and 
leukemia is further underscored by work done by Krause and colleagues, who 
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demonstrated differential disease progression of Bcr-Abl chronic myeloid leukemia 
versus Mll-Af9 acute myeloid leukemia due to changes in parathyroid hormone levels and 
parathyroid hormone receptor expression in osteoblasts44. Schepers and colleagues 
further demonstrate that leukemic cells are able to induce architectural changes in the 
stromal environment that biases bone marrow niches towards supporting leukemic cells 
over normal HSC32. This is consistent in the acute myeloid leukemia model, where 
leukemia cells were observed to decrease the ability of co-cultured stromal cells to 
support normal hematopoiesis concomitant with significant transcriptome changes. Thus, 
aberrations in both HSC intrinsic and extrinsic hematopoietic regulator function can 
contribute towards leukemogenesis. 
Acute myeloid leukemia 
Acute myeloid leukemia epidemiology and treatment 
 Of the four main types of leukemia, acute myeloid leukemia (AML) is the second 
most prevalent leukemia in adult patients. In AML, a block in normal myeloid 
differentiation causes an accumulation of immature, non-functional myeloid precursor 
cells referred to as myeloblasts. Disruption of normal myelopoiesis in AML causes 
deficiencies in mature, functional myeloid cells such as granulocytes. Moreover, 
myeloblast proliferation overtakes the bone marrow compartment and prevents 
development of hematopoietic cells, such as megakaryocytes and erythrocytes. Taken 
together, AML patients often present clinically with symptoms related to the lack of these 
critical blood cells, such as infection, anemia, fatigue, and bleeding disorders. 
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Definitive diagnosis depends largely on clinical presentation, histologic 
verification of blasts with myeloperoxidase bodies called Auer rods, and cytogenetic 
abnormalities associated with AML. AML accounts for approximately 30% of all new 
cases of leukemia and is responsible for about 50% of all leukemia-related deaths30. 
While survival rates differ based on prognostic factors and age, overall 5-year survival 
rates from AML diagnosis remain around 15%, where rates drop as low as 3% with 
increasing age45. Recent studies show that current therapies have low 5-year survival 
rates even with complete disease remission46. AML prognosis depends on a variety of 
risk factors and patient history, including age, performance status, leukemia karyotype, 
history of exposure to radiation or cytotoxic therapies, and history of myelodysplasia47. 
The cytogenetics as determined by karyotype play a major role in stratifying patients into 
poor, intermediate and better risk groups. Older patients, and those with prior radiation or 
chemotherapy exposure (so called secondary leukemias) are more likely to have 
cytogenetics associated with poor risk. 
Many efforts have been made to characterize the specific mutations and 
chromosomal abnormalities in context of leukemogenesis. Interestingly, many mutations 
found in AML, such as activating mutations of Flt3 and c-Kit, have been described in 
other models of cancer. However, a large number of mutations and abnormalities found 
in AML are more specific to hematologic malignancies. In addition to other mutations, 
approximately 50% of AML patients harbor one of the following cytogenetic 
abnormalities: t(8;21), t(15;17), inv(16), and 11q23 rearrangements34,48,49. These events 
are now understood to impair normal functioning of various key transcription factors 
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involved in myelopoiesis. For example, t(8;21) creates the chimera AML1-ETO 
oncoprotein which interferes with normal regulation of myelopoiesis by AML15. As 
described previously, PML-RARα due to t(15;17) causes aberrant RARα/RXR sensitivity 
to physiologic vitamin A and consequently impairs promyelocyte differentiation50. 
Inversions of chromosome 16 are associated with the fusion of myosin head gene MYH11 
with core binding factor gene CBFB34. This chimera results in defective CBFβ activity, a 
critical component of RUNX1 and RUNX2-mediated hematopoiesis. Rearrangements of 
11q23 in leukemia are associated with aberrant MLL function. MLL, otherwise known as 
KMT2A, regulates hematopoiesis through its interaction with other transcription factors 
as a co-activator that recruits methyltransferases to modify histone tails and chromatin 
structure6.  
 The current primary treatment modality for AML includes a combination 
chemotherapy that incorporates cytarabine and an anthracycline, a therapeutic strategy 
that has been the mainstay for over 30 years51. Cytarabine, otherwise known as cytosine 
arabinoside or AraC, is converted to aracytidine triphosphate inside the cell and functions 
as a pyrimidine analog that blocks DNA synthesis upon incorporation into DNA. 
Anthracyclines, such as idarubicin and daunorubicin, intercalate into DNA to similarly 
block DNA and RNA synthesis. This strategy is particularly effective in stunting growth 
of actively proliferating cells due to inhibition of DNA production. In clinic, dosing 
schedules and combination strategies vary depending on patient age and other prognostic 
factors. Regardless of treatment regimen, AML chemotherapy involves a progression of 
treatment phases, starting with induction therapy followed by post-remission therapy. 
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Upon AML diagnosis, patients are subjected to induction therapy that aims to reduce 
leukemic disease burden. In adults, this often involves a “7+3 strategy” where patients 
receive one to two cycles of seven days of cytarabine and three days of anthracycline 
treatment51,52. Regular assessments are made to check for disease remission, where 
patients reduce peripheral white blood cell and bone marrow blast counts to normal 
range. At remission, AML patients receive consolidation therapy, which may include 
multiple cycles of high-dose cytarabine and hematopoietic stem cell transplantation. 
However, major concerns exist in the leukemia field surrounding the current 
mainstay treatment for AML, the most critical of which is regarding the toxicities 
associated with cytarabine and anthracycline treatment. Current AML chemotherapy 
protocols are attributed with severe toxicities, including infection secondary to 
pancytopenia, central nervous system toxicities, hyperbilirubinemia, and fatigue. This is 
largely due to the non-selective nature of cytarabine and anthracycline therapy in that the 
chemotherapies are not able to distinguish between normal and leukemic cells in the 
body. This often results in the deterioration of various tissues and organs that normally 
depend on active proliferation, leading to a wide range of sequelae. In fact, pancytopenia-
related infections comprise 62% of all chemotherapy-related toxicities and have a 5% 
mortality rate53,54. Moreover, anthracyclines have severe cardiotoxicities that may 
preclude patients with pre-existing cardiac medical problems from anthracycline therapy 
and limit administration in older individuals. These toxicities make completion of AML 
chemotherapy regimens extremely difficult for leukemia patients. In one clinical study, 
only 56% adult AML patients under 60 years old were able to successfully complete all 
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rounds of consolidation therapy due to severe toxicities.  
Chemotherapy toxicities can prevent the administration of planned post-remission 
chemotherapy doses, increasing the risk of relapsed disease53,54. Relapsed disease refers 
to recurrent leukemia that arises after a patient reaches disease remission. In all cases of 
AML, five-year relapse rates can range anywhere between 56-72% in intermediate to 
high-risk AML patients. To address these concerns, many efforts have been made to 
understand how to prevent relapsed disease. The current thought in the field suggests that 
a subpopulation of leukemic cells, called leukemic stem cells (LSC), are responsible for 
causing relapsed disease14,38,41,55,56. LSCs are thought to be relatively resistant to 
chemotherapy and are described as those leukemic cells that are able to self-renew and 
re-establish disease. Previous work demonstrates proof-of-concept of this model where 
transplantation of primitive Lin-CD34+CD38- leukemic cells was able to transfer 
leukemia from a diseased mouse into a healthy recipient mouse35. While the exact 
characterization and definition of the LSC population remains under contention, it is 
believed that LSCs function similarly to their normal HSC counterparts in their self-
renewal capacities and relative quiescence. This characteristic of LSCs confers decreased 
sensitivity to chemotherapy drugs that target actively proliferating nature of leukemic 
blast cells. Additionally, the abovementioned studies examining leukemia cells and their 
relationship with the bone marrow microenvironment suggest that LSC-mediated 
restructuring of the niche environment may contribute towards their ability to escape 
chemotherapy cytotoxicity. This was further illustrated by previous work done by Singh 
and colleagues where use of anti-CD44 and anti-CD49d antibodies caused displacement 
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of leukemic cells from the bone marrow and increased their sensitivity to drug 
treatment57. Many trials and studies have revealed, however, that high doses of cytarabine 
in multiple cycles are effective in preventing relapsed disease, possibly due to higher 
concentrations of drugs allowing for greater penetrance and toxicity in otherwise 
resistance cell populations51. Unfortunately, this comes at a price of increased toxicities 
that often prevent completion of post-remission therapy. As a last resort alternative, some 
patients receive allogeneic stem cell transplantation. However, this therapy comes with a 
smorgasbord of additional concerns regarding not only side effects including graft-
versus-host disease, but also financial cost and often the lack of an optimal donor-
recipient match.  
Thus, increasing attention has been drawn towards the search for novel and safe 
therapeutic strategies to replace or support current chemotherapies and improve AML 
prognosis. Much progress has been made in some forms of myeloid leukemias by 
exploiting molecular targets that are specific to the disease.  The translocation of t(15;17) 
has been closely studied in acute promyelocytic leukemia (APML). This chromosomal 
abnormality results in the chimeric fusion oncogene PML-RARα, which is responsible for 
defective function of the retinoic acid receptor RARα. RARα, a known regulator of 
granulocyte development, normally complexes with partner protein RXR to form a 
receptor for retinoic acid or vitamin A. Binding to vitamin A causes conformation 
changes that induce transcriptional activation of key genes involved in granulocytic 
differentiation. In t(15;17) APML, the resultant PML-RARα has decreased sensitivity to 
physiologic levels of vitamin A and leads to a maturation arrest at the progranulocyte 
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stage34,37. However, it is now understood that an all-trans form of retinoic acid (all-trans 
retinoic acid, ATRA) is able to bind to PML-RARα/RXR complexes at higher efficiency 
than physiologic forms of vitamin A. Pharmacologic doses of ATRA have been shown to 
induce neutrophilic differentiation of PML-RARα promyelocytes and allow for rapid 
clearance of promyelocytes, allowing for reduction of disease burden while avoiding the 
toxicities associated with conventional chemotherapies. This treatment breakthrough has 
been incorporated into treatment schemes that have radically changed a very poor 
prognostic category of AML into one of the most curable types of AML58. Many current 
patients with APML are successfully treated with ATRA with arsenic trioxide, a 
combination with minimal toxicity as compared with conventional chemotherapy59. A 
similar treatment success was achieved with BCR-ABL+ CML, where patients are now 
able to achieve sustained disease remission due to the use of imatinib or related 
compounds that exploit the structure of the chimera tyrosine kinase to specifically block 
BCR-ABL activity.  
 
AML1-ETO alone is insufficient for leukemogenesis 
A number of chromosomal abnormalities and genetic mutations have been found 
in AML34. Many of these have been found to cause either aberrant hematopoietic 
differentiation or gain of proliferative advantage. This observation, with support from 
several mouse models of leukemia, laid the foundation for a model describing the 
molecular basis of leukemogenesis where two types of mutations must cooperate to 
develop overt leukemia. In this paradigm, a class 1 mutation occurs that confers a 
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proliferative advantage in leukemic cells, such as activating mutations in receptor 
tyrosine kinases such as Flt3 or c-Kit in AML or BCR-ABL in CML. However, this type 
of mutation alone would fall short of leukemia development and may in some cases result 
in a myeloproliferative disorder. To develop leukemia, these class 1 mutations must be 
paired with mutations causing differentiation arrest, so called class 2 mutations, which 
often involve hematopoietic transcription factors. Together, these two classes of 
mutations lead to the proliferation of leukemic blast cells. 
One of the most common subtypes of AML is associated with a t(8;21) 
chromosomal translocation, which creates the AML1-ETO/RUNX1-CBF2T1 fusion gene. 
Most closely associated with M2 subtype of leukemia per the French-American-British 
classification system (FAB), this chromosomal translocation is associated with up to 20% 
of all cases of myeloid leukemia5,60. Multiple studies have shown that this fusion gene is 
a primary, but insufficient, oncogenic driver of myeloid leukemia5. Prior work has shown 
that AML1-ETO can be detected in mature, fully functional blood cells of patients who 
achieve long-term disease remission in the absence of relapsed disease61,62. Moreover, 
blood spots of newborns have been found positive for AML1-ETO despite absence of 
disease until much later on in life63. AML1-ETO is able to confer a survival advantage to 
HSCs, but induces cell cycle arrest and apoptosis in myeloid progenitors64-66. Thus, 
AML1-ETO expressing HSCs may lie relatively dormant until acquiring additional 
mutations that overcome this detrimental effect and cause leukemia. Knockdown of the 
chimera oncogene using siRNA in AML1-ETO-expressing leukemia cells has shown to 
block cell proliferation and induce differentiation, suggesting that t(8;21) and its resultant 
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chimeric oncogene serve as a class 1 mutation67. The existence of such an “Achilles heel” 
may prove critical in advancing effective targeted therapies in light of recent studies of 
the Cancer Genome Atlas identifying the presence of an average of 5 recurrent “driver” 
mutations in cases of AML and the limited success of targeted treatments such as 
receptor tyrosine kinase inhibitors directed against activating Flt3 mutations68. Such 
treatments appear less effective at eradicating leukemic stem cells69. Better understanding 
of the function of AML1-ETO could lead to new strategies for effective and targeted 
leukemia treatment. 
Molecular function of AML1-ETO 
 Previous reports show transcripts of AML1-ETO consist of the first five to six 
exons of AML1, followed by a breakpoint and ETO message starting between the first 
two exons of ETO5,70,71. AML1/RUNX1 is a member of the AML/CBFα family of 
transcription factors that share a highly conserved Drosophila Runt homology domain72. 
Cell line and mouse model studies have elucidated the role of AML1 as a gatekeeper of 
hematopoiesis through its regulation of various target genes related to hematopoietic 
differentiation. Moreover, loss of Aml1 in mice resulted in premature expiration of mouse 
embryos due to an absence of fetal hematopoiesis73. While AML1 regulation of target 
genes depends on the recruitment of various interaction partners, the ability to interact 
with AML1-specific co-activators and repressors is believed to be lost in the fusion 
oncoprotein due to the loss of the C-terminal interaction domains of AML15. However, 
AML1-ETO is believed to possess the ability to modulate transcription through the 
retention of ETO-dependent regulatory function. Reports have shown that ETO is able to 
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recruit histone deacetylases (HDAC) and other mediators of transcription repression. 
Removal of the C-terminal interaction domain of ETO deterred AML1-ETO function and 
its ability to recruit HDAC complexes74. 
 It is now understood that AML1-ETO contributes to t(8;21) leukemogenesis by 
disrupting normal hematopoietic differentiation and promoting leukemic stem cell self-
renewal capacities. It has been shown that AML1-ETO is associated with leukemic blasts 
and can be found in normal peripheral blood and bone marrow cells of AML patients 
who achieve long-term disease remission5. Moreover, AML1-ETO transcript has been 
found in non-myeloid hematopoietic cells of some t(8;21) leukemia patients62. It is 
believed that AML1-ETO disrupts AML1-dependent hematopoiesis by functioning as a 
“dominant repressive” form of AML1, where retained AML1 regions direct AML1-ETO 
to AML1 target genes and ETO confers the transcriptional repressor activity of the fusion 
protein5,75. This is further underscored by additional studies that demonstrate how AML-
ETO9a, a C-terminus truncated alternative splice variant of AML1-ETO, is able to relieve 
otherwise repressed gatekeepers of cell cycling and differentiation and generate more 
virulent and proliferative leukemia when present in human leukemic and mouse HSC 
cells76-78. Moreover, the presence of AML1-ETO was able to enhance the self-renewal 
capacity of hematopoietic stem cells while conferring deleterious effects on progenitor 
cells, emphasizing the importance of the fusion oncoprotein in affecting hematopoiesis at 
an early stage of differentiation48,65,79. These observations have been further recapitulated 
by the ability to significantly increase longevity and replating efficiency of human 
CD34+ adult peripheral blood and cord blood cells transduced with AML1-ETO35. 
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 Outside of its interplay with AML1 targets and other mediators of hematopoiesis, 
ongoing efforts have revealed how AML1-ETO modulates key signaling pathways to 
further its pro-leukemic effects. Using a zebrafish model querying modulators of AML1-
ETO-induced defects in hematopoiesis, Cox2 inhibition was identified as a potential 
intervention for reversing the effects of AML1-ETO13. Such directed therapy holds 
promise for better targeting of the leukemic stem cells. Cox2 activity has been shown to 
be critical in perpetuating self-renewal capacities of AML1-ETO-expressing 
hematopoietic stem cells through a Cox2-β-catenin-dependent pathway14. Zhang and 
colleagues have shown that mouse bone marrow transduced with AML1-ETO increased 
expression of Cox1 and Cox2 concomitant with increased self-renewability ascertained 
by serial methylcellulose replating. Consistent with previous findings in zebrafish 
described above, the use of select COX inhibitors was able to reverse the increased self-
renewability of AML1-ETO transduced bone marrow cells and interestingly decrease β-
catenin protein levels. Corollary experiments further showed loss of β-catenin was able to 
ablate colony forming efficiency conferred by AML1-ETO transduction in mouse bone 
marrow and t(8;21)-harboring human leukemia cells. This is consistent with a previous 
study that had identified induction of Wnt signaling by AML1-ETO through increased 
expression of plakoglobin, a homolog of β-catenin that shares the ability to induce Wnt-
dependent target gene expression37,80.  
Interestingly, the convergence of Wnt signaling and inflammation has been 
recapitulated in the context of both cancer and normal hematopoietic development. While 
the role of Wnt signaling and inflammation independently have been extensively studied 
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in APC-mutant colon cancer, Castellone and colleagues demonstrated that the two 
pathways converge in colon cancer pathogenesis81. Their work demonstrates that 
induction of COX2 expression and subsequent increase in prostaglandin E2 (PGE2) 
production in colon cancer causes activation of prostaglandin receptor E2. This results in 
the phosphorylation and inactivation of GSK3β, a member of the β-catenin destruction 
complex; leading to the increased stability and nuclear translocation of β-catenin. In the 
context of normal development, previous studies have shown that COX2 and PGE2 play 
central roles in mediating hematopoiesis82. Using a zebrafish model, Goessling and 
colleagues have found a similar convergence of PGE2 and Wnt signaling in mediating 
hematopoietic development83. While addition of PGE2 and Wnt8 was able to stimulate 
hematopoiesis in zebrafish, this effect was reversed with indomethacin treatment as well 
as ectopic expression of axin and a dominant negative form of tcf, suggesting that PGE2 
enhances Wnt signaling-dependent hematopoiesis.  
COX-mediated inflammation and cancer 
 While connections between inflammation and Wnt signaling with oncogenesis 
have been made before, these studies revealed a novel relationship between the three 
players in the context of AML1-ETO leukemia. COX1 and COX2 are the two most 
widely studied members of the cyclooxygenase family of enzymes. Cyclooxygenases 
(COX) are chiefly responsible for the conversion of arachidonic acid to downstream 
metabolites that are responsible for mediating inflammation, including thromboxanes and 
prostaglandin84. The exact regulation of COX and its subsequent inflammatory mediators 
is still being studied. While COX-induced inflammation is responsible for upregulating 
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various inflammatory cytokines, some of these downstream targets are also involved in 
induction of COX expression, such as CEBPb, IL1b, and PTGER485-87. The oncogenic 
relevance of COX-mediated inflammation has been previously described in the context of 
various malignancies including familial adenomatous polyposis and breast cancer88,89. In 
various models of cancer, particularly solid tumors, chronic inflammation in the tumor 
microenvironment has been implicated as a key mediator of angiogenesis and tissue 
remodeling in the niche. These changes are thought to occur concurrently with secretion 
of various pro-inflammatory cytokines that initiate pathways regulating cancer 
proliferation and growth90,91. The relationship between inflammation and carcinogenesis 
has been most extensively studied in the context of colon cancer, where studies have 
demonstrated the role of inflammatory mediators, such as COX and prostaglandins, in the 
regulation of Wnt signaling in APC mutant colon cancer models. The use of COX 
inhibitors, such as celecoxib, has led to significant reduction of adenoma and polyp 
formation92,93. Both pre-clinical and epidemiologic evidence demonstrate the potential 
inverse relationship between anti-inflammatory drug use and breast cancer 
development94,95. Consistent with the above, orthotopic xenograft of melanoma cells in 
mice with enhanced inflammatory predisposition revealed greater tumor growth and 
metastasis compared to control96. Aside from solid tumors, exciting work pursued by 
Schepers and colleagues have revealed the role of inflammatory gene expression and 
signaling in mediating Bcr-Abl+ CML pathogenesis, mainly functioning as a medium for 
leukemia cell to stromal environment crosstalk32. Interestingly, work by Kim and 
colleagues demonstrate loss of stromal culture ability to support normal hematopoiesis 
		
22 
after “pro-leukemic” conditioning by co-culture with leukemic cells97. Taken together, 
these observations elucidate a novel pro-oncogenic effect of inflammation in 
leukemogenesis.  
Wnt signaling and cancer 
Wnt signaling has been widely studied in the context of development and 
carcinogenesis as a key mediator of cell growth, proliferation, and development. Wnt 
signaling initiation depends on the interaction of Wnt ligands with a receptor complex 
formed by members of the Frizzled (Fz) and low-density lipoprotein receptor-related 
protein (LRP) families. There are ten known members of the Fz family, two LRP co-
receptors (LRP5 or LRP6), and 19 different Wnt genes in humans98. While Wnt signaling 
regulates many biologic processes throughout the human body, it is known that their 
specific roles depend on the cellular context as well as the exact combination of particular 
ligands and co-receptors. Particular sets of these Wnt ligands and co-receptors come 
together to trigger three different intracellular Wnt signaling pathways: canonical Wnt, 
Wnt/Ca2+, and Wnt polarity signaling pathways. Canonical Wnt signaling is largely 
dependent on activation of Wnt transcription factors by co-activator β-catenin upon 
nuclear translocation. The Wnt/Ca2+ pathway triggers increases in intracellular calcium 
that activates protein kinase C. While the exact targets of this pathway remain unclear, 
work in Xenopus has revealed the Wnt/Ca2+ pathway works to antagonize and regulate β-
catenin-dependent canonical Wnt signaling. Wnt polarity signaling pathway was first 
described in embryologic studies examining regulators of gastrulation. These studies 
revealed Wnt-dependent activation of cytoplasmic scaffold protein Dsh, which mediates 
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actin and cytoskeletal reorganization.  
In the hematopoietic system, canonical Wnt signaling has been implicated as a 
regulator of hematopoietic stem cell viability and differentiation11. As briefly discussed 
above, canonical Wnt signaling largely depends on the presence of intracellular β-
catenin98,99. While it was first described as an adhesion molecule involved in cytoskeletal 
architecture, free cytoplasmic β-catenin is now understood to be the central player in 
canonical Wnt signaling. In the absence of Wnt ligand binding to co-receptors, a β-
catenin destruction complex comprised of AXIN, APC, CK1, and GSK3β tightly 
regulates cytoplasmic β-catenin via phosphorylation, ubiquitylation, and eventual 
degradation. In the presence of Wnt activation, Wnt ligand binding to Fz and LRP 
inactivates GSK3β resulting in the disassembly of the destruction complex. This leads to 
the accumulation of cytoplasmic β-catenin and subsequent translocation into the nucleus. 
In the nucleus, β-catenin binds with transcription factors, such as TCF/LEF family 
members, and other co-activators such as p300 and CBP, forming a Wnt activation 
complex that promotes Wnt target gene expression. Interestingly, previous studies have 
revealed that only specific Wnt ligands are involved in mediating hematopoiesis via 
canonical Wnt signaling. In mice, bone marrow stromal cells transfected with Wnt1, 
Wnt5a, and Wnt10b specifically were able to induce growth of immature hematopoietic 
progenitor populations100. These findings were further corroborated by similar 
experiments using human stromal cell lines transfected with WNT2B, WNT5A, and 
WNT10B101. Additional experiments have further shown that culturing HSCs in media 
supplemented with recombinant WNT3A was able to increase stem cell self-renewal and 
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maintenance101. However, the role of Wnt signaling in hematopoiesis is complex that 
extends beyond simply a supportive contributor of stem cell maintenance. Scheller and 
colleagues have identified that constitutively activated β-catenin causes HSC 
differentiation block concomitant with increased cell cycle entry, leading to stem cell 
exhaustion12. This observation, in addition to others, created the basis for the idea that 
increased canonical Wnt signaling does not necessarily confer advantages for 
hematopoiesis in a directly proportional manner. Using varying APC mutant mouse 
models to create gradients of Wnt signaling activation, Luis and colleagues have shown 
that while milder increases in Wnt signaling enhance HSC function, super-physiologic 
increases of Wnt signaling prove to be detrimental to HSC self-renewal and 
differentiation10. Moreover, different hematopoietic processes, such as T-cell versus 
myeloid differentiation, have varying optimal amounts of Wnt signaling increases, 
suggesting that pro-hematopoietic Wnt signaling exists in a gradient that is development-
specific rather than a binary relationship with hematopoiesis. 
 In addition to the aforementioned studies examining its role in AML, Wnt 
signaling has been studied in the context of other types of hematologic malignancies. 
Other leukemias, including both acute and chronic lymphocytic leukemias, have 
dysregulated increases in Wnt gene expression37. Other oncogenic chimera genes, such as 
E2A-PBX1 in pre-B-cell acute lymphocytic leukemia, cause increased expression of Wnt 
genes that may result in abnormal regulation of Wnt signaling102. Jamieson and 
colleagues have further demonstrated that Wnt signaling is involved in triggering blast 
crisis in BCR-ABL+ CML, possibly due to Wnt-activating second hit mutations or 
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events103. However, additional studies, especially those pursued by Liang and colleagues, 
demonstrate that non-canonical Wnt/Ca2+ signaling due to Wnt5a may have tumor 
suppressive roles by inhibiting canonical Wnt signaling activation in certain B-cell 
lymphomas and myeloid leukemias104. Thus, the role of Wnt signaling in hematologic 
malignancies is similar to that of the gradient-like relationship Wnt signaling has with 
hematopoiesis and goes beyond a simplistic view that increased Wnt signaling is strictly 
oncogenic. 
Cooperating events with AML1-ETO in t(8;21) leukemia 
 Extensive evaluations of AML1-ETO function indicate that the presence of AML1-
ETO alone is insufficient to fully drive leukemia development. The presence of the 
AML1-ETO fusion gene has been demonstrated in the blood spot of newborns who did 
not develop leukemia for over 10 years61,63,105. The development of a transgenic mouse 
with myeloid-specific AML1-ETO expression revealed the expression of AML1-ETO 
alone did not generate leukemia and required additional cooperating mutations as induced 
by treating AML1-ETO-expressing mice with ENU, a DNA-alkylating agent106. Another 
mouse model targets AML1-ETO in hematopoietic stem and progenitor cells via AML1-
ETO insertion into the Sca-1 locus107. While these mice do develop myelodysplastic 
syndrome-like phenotypes over time, they do not develop myeloid leukemia on their 
own. Transplantation of the above-described AML1-ETO transduced CD34+ human cells 
into mice failed to produce leukemia in mice as well35. Outside of mouse models, 
Kasumi-1 and SKNO-1 cell lines, two human leukemia cell lines with endogenous 
AML1-ETO expression, are frequently used to study AML1-ETO leukemia. Both cell 
		
26 
lines are derived from a human patient with t(8;21) AML, but were found to also harbor 
an activating mutation of c-Kit and inactivating mutation of p53, respectively108,109. 
These concomitant mutations are thought to contribute towards the immortalization and 
proliferation of the leukemic cells and further echo the need for a “second hit” to 
propagate AML1-ETO leukemogenesis.  
 The observations described above suggest that AML1-ETO is involved in 
disrupting myeloid development at an early progenitor stage and require additional 
cooperating events to induce florid myeloid leukemia. We have postulated that the 
leukemic potential of AML1-ETO is held in check by potential tumor suppressor genes, 
the discovery of which might have significant therapeutic implications. In search of such 
mutations, our laboratory noted that, other than losses or gains of chromosomes X,Y or 8, 
an interstitial deletion of chromosome 9q is the most common secondary cytogenetic 
change associated with t(8;21) AML48,49,110. This finding prompted our laboratory’s 
initial efforts to identify a potential AML tumor suppressor gene on 9q. After mapping 
the commonly deleted region in del(9q) AML, our laboratory previously used shRNA to 
target all candidate genes located in the commonly deleted region. This revealed 
knockdown of two neighboring genes, TLE1 and TLE4, counteracted the cell apoptosis 
and lethality of myeloid progenitors induced by AML1-ETO48,49. They further 
demonstrated that knockdown of TLE4 stimulated proliferation and decreased apoptosis 
of Kasumi-1 cells, opposite the effect seen with induced expression of TLE4. 
Furthermore, loss of the TLE homologue, Gro3, in zebrafish cooperated with AML1-ETO 
to create a myeloid leukemia phenotype48. This indicated that TLE4 might be a critical 
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gatekeeper blocking the oncogenic potential of AML1-ETO and underscored the 
importance of elucidating the mechanism behind the synergistic effects of AML1-ETO 
and loss of TLE4.  
The Groucho/TLE family of co-repressors 
Discovery of Gro in Drosophila 
 The Groucho/TLE family of proteins has been characterized as master regulators 
in Drosophila development because of their regulation of multiple signaling pathways 
and critical roles in many cell fate decisions111-114. First described in 1968, mutations in 
Gro, the Drosophila homolog of TLE, resulted in bristle formation in Drosophila that was 
reminiscent of the iconic bushy eyebrows of comedian Groucho Marx. Studies showed 
this phenotype was mediated by the role of Gro in mediating regulation of lateral 
inhibition and neurogenesis through Notch signaling in Drosophila115. Later studies 
described the predominately nuclear localization of Gro. Previous work examining the 
interaction between Gro and Hairy-related proteins was one of the first descriptions of 
Gro functioning as a transcriptional co-repressor114. Additional work in Drosophila has 
identified other interaction partners with Gro. Through work examining the interactions 
between the Runt family proteins and Gro, it is now understood that the short peptide 
motif VWRPY is able to recruit the co-repressor Gro to various transcription factor 
partners116. Other work has shown that Gro functions as a co-repressor of dTcf, the 
Drosophila homolog of TCF, in the absence of a Wnt signal117. More recent work has 
demonstrated the role of Gro in epigenetic regulation via its recruitment of PRMT5, a 
histone methyltransferase, and subsequent histone tail modification118.  
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Gro homolog Tle in Mouse 
 In mammals, there are six members of the TLE/Groucho family: TLE1, TLE2, 
TLE3, TLE4, TLE6, and AES. The TLE/Groucho family members have a highly 
conserved amino-terminal Q domain that is responsible for coiled-coil structures that 
enable homo- and hetero-tetramerization, an essential conformation for effective TLE co-
repressor activity. The homologs also share a conserved WD-repeat domain at the C-
terminus that is responsible for protein-protein interaction. The loss of this region in the 
truncated homolog AES is thought to be responsible for conferring its dominant negative-
like function and subsequent regulation of TLE-mediated transcription repression115. 
Consistent with observations of Gro in Drosophila, various studies have found high levels 
of TLE expression in cell determination events during mouse embryonic segmentation, 
neurogenesis, and epithelial differentiation119,120.  
Additional studies have demonstrated the TLE family of co-repressors is able to 
interact with mammalian homologs of Hairy and Runt family transcription factors as well 
as TCF/LEF to exert a regulatory role in various signaling pathways, including Notch and 
Wnt signaling. In normal Notch signaling activation, ligand binding to Notch receptors 
triggers a cleavage of the transmembrane receptor. This results in the release of the 
intracellular component, otherwise known as the Notch intracellular domain (NICD), 
which functions as a transcription factor and mediate Notch target gene expression. TLE 
regulates Notch signaling through its co-repressor function. TLE binds to HES1, a key 
NICD target gene and downstream mediator of Notch signaling, and forms a TLE/HES1 
complex that turns off HES1 transcriptional activation. This relationship between TLE 
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and Notch signaling is responsible for Groucho/TLE-dependent neurogenesis and lateral 
inhibition that was first described in Drosophila and the Groucho namesake described 
previously. In addition to this role as a downstream effector of Notch signaling, the TLEs 
bind to RBP-J proteins, which together provide basal repression of Notch targets121. 
Additionally, TLE and its co-repressor function play a pivotal role in regulating canonical 
β-catenin-dependent Wnt signaling. TLE is known to bind with Wnt signaling 
transcription factor TCF/LEF in the absence of Wnt signaling. This causes the co-
repressor to switch off transcriptional activation by TCF/LEF. Moreover, though the 
mechanism is not completely understood yet, TLE prohibits other Wnt co-activators, 
such as CBP and β-catenin, from binding with TCF/LEF. In the presence of Wnt 
signaling, the TLE-TCF/LEF interaction is terminated, possibly through TLE 
ubiquitylation by XIAP or direct displacement by β-catenin, and subsequent displacement 
of TLE from TCF/LEF. This allows for TCF/LEF interaction with various co-activators 
and allow for Wnt signaling-mediated transcription122.  
The importance of the co-repressor function of Groucho/TLE in various processes and 
signaling pathways has led to increased interest in understanding the role of TLEs in 
various cancers48,123-126. Riz and colleagues have shown that TLE-mediated repression is 
central to regulating Notch and TLX1-dependent transcriptional activity, both aberrantly 
hyper-activated transcriptional regulators in T-cell acute lymphoblastic leukemia127. In a 
separate study of AML, Steffen and colleagues have shown that AML1-ETO induces 
expression of AES, a dominant negative-like truncated isoform of TLE128. AES inhibits 
normal transcriptional regulation of TLE and contributes to AML1-ETO leukemia cell 
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proliferation and self-renewal. However, TLE does not strictly function as a tumor 
suppressor in all malignancies and its co-repressor role can be pathogenic in a context-
dependent manner. In glioblastoma multiforme, Verginelli and colleagues demonstrate 
the oncogenic contribution of FOXG1-mediated transcriptional repression, which is 
mediated through its binding interaction with TLE1124. Additionally, TLE1 mediates 
oncogenic function of chimeric oncoprotein SSX-SS18 in t(X;18) synovial cell 
sarcoma126. SSX-SS18 is known to derive its oncogenic potential by interfering with 
normal ATF2-mediated transcription by recruiting TLE1 and inactivating target gene 
expression. In fact, this mechanistic relationship between TLE1 and SSX-SS18 and the 
strong association of TLE1 with synovial cell sarcoma development has led to the use of 
TLE1 immunohistochemistry in patient samples as a diagnostic tool.  
Generation of Tle4 knockout mouse model 
 Despite our understanding of Gro in Drosophila, there is a very limited body of 
literature describing its role in mammalian development. To understand the role of Tle4 
in development, previous members in our laboratory have generated a novel Tle4 null 
mouse (T4KO) that has constitutive loss of Tle4113. These mice generally expire by three 
weeks of life and have significant developmental defects, including aberrant 
hematopoiesis and bone development. My colleagues have shown loss of Tle4 in mice 
cause deficiencies in B cell development and hematopoietic stem cell depletion. These 
findings have guided experiments described in this dissertation to examine the effect of 
Tle4 loss on hematopoietic stem cell function and bone development. In addition to the 
T4KO model, experiments in this work have utilized a conditional Tle knockout mouse 
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model that has also been developed by my predecssors in the laboratory. Conditional Tle 
knockout was made possible by exploiting the Cre-Lox system where Cre recombinase 
targets specific target sequences in DNA known as LoxP sites. By specifying Cre 
recombinase expression in tissue-specific promoters, the Cre-Lox system allows for 
targeted excision of DNA sequences flanked by LoxP sites in isolated tissue 
compartments. This was an advantageous model to bypass problems related to limited 
sample availability and early death in constitutive Tle4 null mice. To study the role of Tle 
in the bone and hematopoietic compartment, our model exploited the myxovirus 
resistance-1 (Mx1) promoter. Mx1 is expressed by members of the hematopoietic and 
bone marrow stromal compartments and is responsive to interferon-γ signaling43,129. 
Other studies have shown that injecting pIpC, an analog of double-stranded RNA, was 
able to stimulate an anti-viral interferon-γ response and subsequently induce expression 
of an Mx1-cre gene specifically in hematopoietic stem cell and stroma-specific excision 
of target sequences43,129. In our model, our laboratory has inserted LoxP sites flanking 
exon 2 of Tle, which includes the critical Q-domain of Tle and leads to a frameshift 
creating an early termination codon. This Q-domain is essential for successful 
tetramerization and co-repressive function of Tle113,115. While my colleagues have found 
that it successfully bypasses lethality due to constitutive Tle knockout, additional 
characterization of this knockout mouse model are underway to examine whether induced 
excision post-birth can lead to similar development defects observed in the T4KO mouse 
model. 
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Specific aims and hypothesis 
 For my thesis dissertation, I have pursued two projects examining the role of 
TLE4 in the contexts of t(8;21) AML and normal development. I have used the Kasumi-1 
model of t(8;21) AML with shRNA knockdown of TLE4 to understand the molecular 
mechanism behind the cooperation between AML1-ETO and loss of TLE4. I have aimed 
to characterize the pro-leukemic effects of TLE4 knockdown in Kasumi-1 cells by 
demonstrating its effects on cell proliferation, apoptosis, and chemotherapy resistance. 
By utilizing RNAseq, I have sought to identify enrichment of novel pathways that are 
modulated due to perturbed TLE4 levels. I hypothesized that these findings would 
identify key TLE4-regulated mediators of AML1-ETO leukemia that can be used for 
developing targeted treatment strategies for AML.  
 Working with colleagues in the laboratory, I have also pursued experiments that 
further characterized the role of Tle4 loss on hematopoiesis. I hypothesized that these 
abnormalities would play a significant role on the viability and intrinsic maintenance of 
Tle4 null hematopoietic stem cells. I have evaluated these effects using cell proliferation, 
apoptosis, and serial methylcellulose colony forming unit assays. An additional 
unexpected striking phenotype in Tle4 null mice was a severe defect in bone 
mineralization. Given the importance of osteoblasts in bone development and HSC 
maintenance, I hypothesized that loss of Tle4 significantly impacts osteoblast function 
and development. By using mineral apposition rate assays, microCT imaging, and bone 
histology, I sought to capture both dynamic and static bone formation parameters as 
indices of osteoblast function. Moreover, I further hypothesized that expression analyses 
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and alkaline phosphatase staining of Tle4 null stromal cultures would demonstrate 
significant reductions in key regulators and markers of osteoblast differentiation. 
 The results of these experiments provide an insightful examination into novel 
regulatory roles of TLE4 as a tumor suppressor in myeloid leukemia and a mediator of 
hematopoietic development and mammalian bone formation, a critical component of the 
hematopoietic stem cell niche. Various studies of leukemogenesis and myelodysplastic 
syndrome have implicated crosstalk between leukemic stem cells and the HSC niche as a 
contributor towards remodeling of the niche into a pro-leukemic environment32,97. The 
implications of these studies may shed new light on current understanding of how 
inflammatory pathways involved in AML1-ETO leukemogenesis may impact pro-
leukemic remodeling of the HSC niche and ultimately lead to new strategies to eliminate 
leukemia.  
.
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CHAPTER TWO: MATERIALS AND METHODS 
Cell culture, shRNA construction, and lentiviral infection 
 Kasumi-1 cells (ATCC, Manassas, VA) were cultured in RPMI-1640 (Lonza, 
Walkersville, MD) supplemented with 10% FBS (Sigma, St Louis, MO) and 1% 
Penicillin/Streptomycin (Invitrogen, Carlsbad, CA). HL60 cells (ATCC) were cultured in 
MEMα (Invitrogen) supplemented with 20% FBS and 1% Penicillin/Streptomycin 
(Invitrogen). All cells were maintained at 37°C and 5% CO2 and leukemia cells were 
cultured at concentrations of 106 cells/mL. ST2D cells (Generous gift of Dr. Baruch 
Frenkel) were generated by stably transforming mouse mesenchymal ST2 cells derived 
from bone marrow with a doxycycline-inducible Runx2 expression vector27. ST2D cells 
were cultured in RPMI-1640 (Lonza) supplemented with 10% FBS (Sigma) and 
penicillin/streptomycin. When indicated, cells were also cultured with the following 
compounds and concentrations: 10uM all-trans retinoic acid (Sigma), 50uM 
indomethacin (Sigma), 100uM cytarabine (Abcam, Cambridge, MA), 0.1uM vitamin D3 
(Sigma), 10nM recombinant human Wnt3a (R&D Systems, Minneapolis, MN), 10uM 
ICG-001 (Selleck Chemical, Houston, TX), or 250ng/mL doxycycline (Sigma).  
 Non-targeting scramble control and TLE4-specific shRNA constructs were 
developed and delivered to cells via lentiviral delivery as previously described48. The 
shRNA used and their target sequences were: shTLE4_1 
(AGTGATGACAACTTGGTGG) and shTLE4_2 (GGCATTATGTCATGTATTA). Data 
in figures were obtained using shTLE4_2 unless otherwise indicated. Infected cells were 
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identified by GFP fluorescence detected using FACS LSRII or selected for via cell 
sorting with FACS Aria (BD, San Jose, CA).  
 
Generation of Tle4 null and conditional Tle1/Tle4 knockout mice 
 Our laboratory has generated Tle4 null (T4KO) and Tle1 and Tle4 conditional 
knockout mice as previously described113. Briefly, conditional Tle4 (T4F) and Tle1/4 
(T14F) null mice were constructed by targeting LoxP sites to flank exon 2 via 
homologous recombination using the 129S6/SvEvTac ES cell line. To generate T4KO, 
resultant mice were crossed with β-actin:Cre mice (gift of Dr. Susan Dymecki) to delete 
exon 2 in all tissues. Heterozygote mice were backcrossed to C57BL/6 background for 
over 6 generations and interbred to generate Tle4 null mice. For conditional knockout of 
Tle1 and Tle4, T4F and T14F mice were crossed with Mx1-Cre (T4F cre and T14F cre, 
respectively). Excision of Tle1 and Tle4 exon 2 was induced with three intraperitoneal 
injections of 15mg/kg polyinosinic-polycytidylic acid (pIpC; Sigma) every 48 hours. 
 
Flow cytometry analysis and cell sorting 
 Cell cycling and death in Kasumi-1 cell populations were determined using DAPI 
cell cycle and Annexin V assays as previously described48. When indicated, the following 
fluorescent anti-human antibodies were used: CD11b-APC (eBiosciences, San Diego, 
CA), CD14-APC-Cy7  (Biolegend, San Diego, CA), APC-Annexin V (BD), DAPI 
(Invitrogen). 
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 The following anti-mouse antibodies were used for flow cytometry analysis:  
biotin-lineage cocktail (B220, CD3e, CD11b, Gr-1, Ter119; BD), streptavidin-APC-Cy7 
(eBiosciences), streptavidin-Pacific Orange (eBiosciences), Sca1-BV421 (Biolegend), c-
Kit-PE (eBiosciences), Gr-1-PE (eBiosciences), CD48-Pacific Blue (eBiosciences), and 
CD150-PE-Cy7 (eBiosciences). Antibodies for Annexin V and anti-mouse Ki-67 assays 
were used as per manufacturer’s protocol (BD). 
 All flow cytometry data was analyzed using FlowJo X (Treestar, Ashland, OR) 
and ModFit LT 3.0 (Verity Software House, Topsham, ME). Cells were sorted using 
FACS Aria (BD) or analyzed using FACS Aria, Calibur, or LSRII (BD). 
 
Detection of Wnt signaling 
 To detect Wnt signaling activity in Kasumi-1, a TOPdGFP reporter construct 
containing 8x LEF promoter binding sites followed by destabilized GFP with a short 
half-life was used (Gift of Dr. Randy Moon). Nucleofection was achieved using Amaxa 
Nucleofector II (Lonza) and protocol U-08. Kasumi-1 cells were nucleofected with 
TOPdGFP (a destabilized GFP with short half-life) with abovementioned scramble 
control or TLE4-specific shRNA inserted into expression vector pcDNA-zeo. GFP mean 
fluorescence intensity was measured 24 hours post-nucleofection using FACS Aria (BD).  
 Wnt activity was also measured in 293T cells (ATCC) using a 
TOPFLASH/FOPFLASH assay. Briefly, 293T cells were transfected with the following 
reporter constructs using TransIT reagent (Mirus Bio, Madison, WI): TOPFLASH 
construct containing 8x promoter binding sites followed by firefly luciferase, 
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FOPFLASH firefly luciferase control, and pRL renilla luciferase transfection control. 
293T cells were additionally transfected with abovementioned shRNA constructs and/or 
expression vectors containing AML1-ETO, CBFb, and TLE4. Treated cells were 
subsequently analyzed using MicroLumat PLUS LB luminometer (Berthold 
Technologies, Bad Wildbad, Germany) and Dual-Luciferase Reporter Assay System 
(Promega, Madison, WI) 24 hours post-transfection. 
 
Western Blotting 
 Kasumi-1 and 293T cells treated with TLE4-specific or scramble control shRNA 
were similarly lysed for protein, run, and probed using the following antibodies: anti-
human TLE4 (Santa Cruz Biotechnology, Dallas, TX), anti-Actin (Santa Cruz 
Biotechnology), donkey anti-goat IgG-HRP (Santa Cruz Biotechnology), and goat anti-
rabbit IgG-HRP (Abcam). Protein lysates of bone and osteoblast-like cells from Tle4 
wildtype (T4WT) and T4KO mouse samples of above co-culture experiments were 
prepared for western blot as previously described31. Western blots were probed with anti-
mouse antibodies to Tle4 (Abcam), Gapdh (Abcam), stem cell factor (Scf; Santa Cruz 
Biotechnology) and mouse b-actin (Santa Cruz Biotechnology), followed by horseradish 
peroxidase conjugated secondary antibodies (Santa Cruz Biotechnology). Blots were 
visualized by chemoluminescence (Pierce ECL, Thermo Scientific, Rockford, Ill).  
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Expression analysis via RNAseq and qRT-PCR 
 For RNAseq, RNA was harvested from Kasumi-1 cells using TRIzol (Invitrogen) 
7 days after lentiviral spinoculation with scramble control or TLE4-specific shRNA. 
Library construction was performed after polyA-tail selection and used for 50bp paired-
end reads that were aligned to human genome GRCh37.75 using STAR and quantified 
using HTSeq. DESeq was used for normalization and identification of differentially 
expressed genes. Gene Set Enrichment Analysis (GSEA; Broad Institute, Cambridge, 
MA) was performed via Java application by ranking genes using t-scores. Expression 
levels of select differentially expressed genes and others of interest were performed using 
qRT-PCR as previously described113.  
 RNA from mouse, Kasumi-1, 293T, and HL-60 cells were prepared using TRIzol 
(Invitrogen) per manufacturer’s instructions. Primer sequences for SYBR Green and 
catalog numbers for Taqman assays (Invitrogen) are listed in Tables 1-3 
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Table 1. List of human primers used for SYBR Green qRT-PCR 
 
Forward (5' to 3') Reverse (5' to 3') 
B2M ATTCGGGCCGAGATGTCT GAATCTTTGGAGTACGCTGGA 
COX1 TGTTCGGTGTCCAGTTCCAATA ACCTTGAAGGAGTCAGGCATGAG 
COX2 CCTTCCTCCTGTGCCTGATG ACAATCTCATTTGAATCAGGAAGCT 
PTGER4 CGCTGTCCTCCCGCAGACGA CCACCCCGAAGATGAACATC 
CEBPB CTTCAGCCCGTACCTGGAG GGAGAGGAAGTCGTGGTGC 
LEF1 GACGAGATGATCCCCTTCAA CGGGATGATTTCAGACTCGT 
FOS CCTCCTGTCATGGTCTTCACA GTCTCCAGTGCCAACTTCATT 
CCND3 CTGCCTCCAGGAACCACA GCTTGACTAGCCACCGAAAT 
IL1B TTTTTGCTGTGAGTCCCCGAG TTCGACACATGGGATAACGAGG 
CEBPA GAGGAGGGGAGAATTCTTGG CATTTCCAAGGCACAAGGTT 
GATA1 CATGCGGAAGGATGGTATTCAG CTCCCCACAATTCCCGCTAC 
PU.1 ATGGAAGGGTTTCCCCTCGT CCAGTAATGGTCGCTATGGCT 
MYB ACAGAAATACGGTCCGAAACG CCAATTCTCCCCTTTAAGTGCT 
MPO AGACCTGCTGGAGAGGAAGCT CGCAGCCGCTTGACTTG 
ELANE GTGGCCGACCCGTTGAG CCACCCGGCAGGTGTTC 
 
Table 2. List of mouse primers used for SYBR Green qRT-PCR 
 
Forward (5' to 3') Reverse (5' to 3') 
Oc ACAAGTCCCACACAGCAGCTT GCCGGAGTCTGTTCACTACCT 
Osx GTACGGCAAGGCTTCGCATCTG CTGATGTTTGCTCAAGTGGTCGC 
Opg GGCCTGATGTATGCCCTCAA GTGCAGGAACCTCATGGTCTTC 
Spp1 CCCGGTGAAAGTGACTGATTCT GATCTGGGTGCAGGCTGTAAA 
Ap CACAGATTCCCAAAGCACCT GGGATGGAGGAGAGAAGGTC 
Runx2 GCCGGGAATGATGAGAACTA GGTGAAACTCTTGCCTCGTC 
18s CGGAAATAGCCTTCGCCATCAC ATCACTCGCTCCACCTCATCCT 
 
Table 3. List of TaqMan primer mixes used for qRT-PCR 
Human TaqMan primer Mouse TaqMan primer 
KLF6 Hs00810569_m1 Tle1 Mm00495643_m1 
ITGAL Hs00158218_m1 Tle2 Mm00498094_m1 
IFIT1 Hs01911452_s1 Tle3 Mm00437097_m1 
TLE4 Hs00419101_m1 Tle6 Mm0475103_m1 
  
Aes Mm00507851_g1 	  
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Primary human AML patient samples 
 Diagnostic bone marrow specimens from human acute myeloid leukemia (AML) 
patients with del(9q) or t(8;21) del(9q) were obtained from the Children’s Oncology 
Group as described previously48. RNA was harvested from samples using TRIzol 
(Invitrogen) for qRT-PCR assays described above. CD34+ cells from normal donors 
were similarly treated and processed for RNA after informed consent and assent from 
parents and patients in accordance with protocols approved by Massachusetts General 
Hospital Institutional Review Board and Children’s Oncology Group Myeloid Disease 
Committee. 
 
Leukemia transplantation models  
 To generate Tle4 null models of myeloid leukemia, two to three-month old T4F 
and T4F cre mice were treated with three intraperitoneal injections of 15mg/kg pIpC 
(Sigma) for Tle4 excision as well as 200mg/kg 5-Fluorouracil (APP Pharmaceuticals, 
Schaumburg, IL) intravenously. One week later, whole bone marrow from mice was 
cultured in pre-stimulation media comprised of DMEM supplemented with 6ng/mL 
recombinant murine IL-3 (Peprotech, Rocky Hill, NJ), 20ng/mL recombinant murine IL-
6 (Peprotech), 100ng/mL recombinant murine Scf (Peprotech), 1ug/mL ciprofloxacin 
(Invitrogen), 15% FBS (Sigma), 1% Penicillin/Streptomycin (Invitrogen), and L-
glutamine (Invitrogen). Bone marrow cells were subsequently spinoculated with MSCV-
AML1-ETO-IRES-GFP or MSCV-AML-ETO9a-IRES-GFP via retrovirus supplemented 
with 2ug/mL polybrene (Sigma) twice every 24 hours. Transduced bone marrow was 
		
41 
subsequently transplanted into wildtype recipient mice after two doses of 450cGy 
sublethal irradiation. Recipient mice were tracked for survival and bled retro-orbitally for 
analysis of GFP+ Gr-1+ peripheral blood cells by FACS Calibur (BD). 
 
Mineral apposition assay, trichrome staining, and MicroCT 
 For mineral apposition assay, five-month old T4F and T4F cre littermates were 
irradiated with two doses of 450cGy and subsequently transplanted with 1x104 wildtype 
Lineage- c-Kit+ Sca-1+ (LKS) cells via tail vein injection. Wildtype LKS cells were 
isolated using a FACS Aria (BD). Eight weeks after transplant, Tle4 excision was 
induced by three pIpC (Sigma) intraperitoneal injections at a dose of 15mg/kg every 48 
hours. Four weeks after Tle4 excision, recipient mice were pulsed with 20mg/kg calcein 
(Sigma) via intraperitoneal injection. After one week, recipients were given 30mg/kg 
demeclocycline (Sigma) via intraperitoneal injection. Femurs were harvested three days 
after demeclocycline injection and fixed in 70% ethanol. Femurs were processed for resin 
embedding for mineral apposition rate analysis or trichrome staining. 
 
Terminal Deoxynucleotidyl transferase dUTP nick end labeling Stain (TUNEL) 
 Paraffin-embedded humeri harvested from two-week old T4WT and T4KO mice 
were sectioned for TUNEL staining using the Apoptag kit per manufacturer’s protocol 
(EMD Millipore, Billerica, MA). Briefly, sections were bathed in Tris buffer with Tween 
X, followed by proteinase K, peroxidase block, and TdT enzyme treatments. All 
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antibodies used for TUNEL staining were included in the kit and sections were 
counterstained using Methyl Green. 
 
Stromal co-culture and serial replating colony forming unit (CFU) assay 
 For methylcellulose colonies using T4KO mice, whole bone marrow from two-
week old T4WT and T4KO mice were lineage depleted using Biotin-conjugated lineage 
antibody cocktail (BD) and Streptavidin magnetic microbeads (Miltenyi Biotec, 
Cambridge, MA). Cells were subsequently sorted by flow cytometry to isolate LKS cells. 
1x103 sorted LKS cells from each cohort were plated in M3434 Methocult (Stem Cell 
Technologies, Vancouver, CA) according to the manufacturer’s protocol. Colonies were 
manually counted 7 and 14 days after plating for serial replating and colony 
differentiation assays, respectively. 
 Stromal co-culture was performed as previously described113,130. Briefly, cells 
from crushed bones of three-day old T4KO or T4WT littermates were grown for two 
weeks in 20% FBS in α-MEM supplemented with Penicillin/Streptomycin (Invitrogen). 
After reaching confluence, media was changed to osteogenic media containing 100µM β-
glycerophosphate, 2.84µM ascorbic acid, and 10nM dexamethasone. Three weeks after 
osteogenic induction, 100 Lineage- c-Kit+ Sca-1+ CD34- CD48- CD150+ cells were 
sorted directly onto osteoblastic stromal cells and allowed to expand for two or four 
weeks. Flow analysis for c-Kit and Sca-1 expression was performed two weeks after 
initiation of co-culture. After four weeks of co-culture, 1x103 cells from each co-culture 
assay sample were seeded in Methocult 3434 (Stem Cell Technologies) and assessed for 
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colony forming units by manual count one week later.  
 For methylcellulose assays using T14F and T14F cre mice, Tle excision was 
induced by pIpC as described above. Mice were subsequently given 200mg/kg 5-
fluorouracil (APP Pharmaceuticals) intravenously and sacrificed five days later for bone 
marrow harvest. Harvested marrow was cultured in pre-stimulation medium as previously 
described131. Cells were subsequently transduced with MSCV-AML1-ETO-IRES-GFP or 
MSCV-IRES-GFP empty vector via retrovirus supplemented with 2ug/mL polybrene 
(Sigma) twice every 24 hours. Lineage- GFP+ cells were positively selected using FACS 
Aria (BD). 1x103 sorted cells were plated in M3434 media (StemCell Technologies) per 
manufacturer’s protocol. Colonies were manually counted and serially replated at each 
timepoint. 
 
Stromal culture and alkaline phosphatase staining 
 Stromal cultures were generated from bones of one-week old T4WT or T4KO 
littermates. After harvesting femur and humeri, whole bones were crushed and plated on 
tissue culture plates with MEMα (Invitrogen) supplemented with 20% FBS and 
Penicillin/Streptomycin (Invitrogen). After three days, non-adherent cells were removed 
and media was changed to osteogenic media containing 100µM β-glycerophosphate, 
2.84µM ascorbic acid, and 10nM dexamethasone. After one week in osteogenic media, 
stromal cultures were either stained for alkaline phosphatase activity (Sigma) or lysed 
with Trizol (Invitrogen) for RNA. 
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 In osteoblast function experiments, ST2D cells were treated with Tle4-specific or 
scramble control shRNA via lentivirus similar to Kasumi-1 and HL60 cell experiments 
described above. One week after spinoculation, GFP+ ST2D cells were selected using 
FACS Aria (BD) and cultured in 6-well plates. Upon reaching confluence, ST2D cells 
were cultured in osteogenic media with or without 250ng/mL doxycycline. After two 
days, ST2D cultures were stained for alkaline phosphatase activity (Sigma) or lysed with 
Trizol (Invitrogen) for RNA. 
 
Animal ethics statement 
 This study was carried out in strict accordance with recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. 
The study was executed under permit #2004N000277, approved by the Massachusetts 
General Hospital Institutional Animal Care and Use Committee.  
 
Statistics 
 Unless otherwise specified, analyses used student’s unpaired t-test or two-way 
ANOVA with Graphpad Prism (Graphpad Software, La Jolla, CA). For RNAseq 
analyses, significantly differentially expressed genes were identified by false discovery 
rate < 0.2. 
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CHAPTER THREE: TLE4 REGULATION OF WNT-MEDIATED 
INFLAMMATION UNDERLIES ITS ROLE AS A TUMOR SUPPRESSOR IN 
t(8;21) LEUKEMIA 
Rationale 
 Our laboratory has previously provided evidence for a putative tumor suppressor 
role of TLE4 in t(8;21) AML48,49. The presence of AML1-ETO is now understood to be 
necessary but insufficient for t(8;21) leukemogenesis61,63,105.  We have further identified 
that the loss of TLE4 due to del(9q), one of the most common concomitant chromosomal 
abnormalities associated with t(8;21) AML, conferred pro-leukemic effects that 
cooperates with AML1-ETO48,49. In my thesis project, I sought to identify the molecular 
basis of the cooperation seen between AML1-ETO and loss of TLE4. Using shRNA-
mediated knockdown of TLE4, I first queried whether Kasumi-1 cells, a t(8;21) human 
leukemic cell line, are sensitive to changes in TLE4 levels. Using RNAseq and qRT-PCR 
validation, I aimed to use an unbiased approach to identifying the mechanism behind this 
relationship in order to uncover new therapeutic targets for AML1-ETO leukemia.  
 
Results 
TLE4 knockdown increases proliferation, decreases cell death, and blocks differentiation 
of t(8;21) leukemic cells 
 To determine the leukemogenic effects of TLE4 knockdown (T4KD), Kasumi-1 
cells were treated with scramble control or two different TLE4-specific shRNAs via 
lentivirus. All experiments used shTLE4_2 for T4KD unless otherwise specified. 
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Effective T4KD was confirmed by qRT-PCR and western blotting (Figure 1A and B). 
shRNA treated cells were tracked over a period of 18 days to monitor cell growth. 
Consistent with previous studies48, TLE4 knockdown in Kasumi-1 cells using two 
different shRNA conferred significantly faster growth compared with their control 
counterparts (Figure 2A). DAPI cell cycle and Annexin V analysis with T4KD Kasumi-1 
cells seven days post-infection showed increased S/G2/M-phase cells concomitant with 
decreased dead cell populations (Figure 2B and C). qRT-PCR further shows significant 
reduction of AML1-ETO repressive targets CEBPa and GATA1, suggesting T4KD may 
be enhancing AML1-ETO activity7,13 (Figure 2D).  
 ATRA is known to be a potent differentiating agent for myeloid cells and 
Kasumi-1 cells respond to ATRA by upregulating CD14132. As a preliminary study of 
how TLE4 knockdown affects differentiation potential, we found T4KD did significantly 
repress ATRA induction of CD14 expression (Figure 2E), suggesting T4KD can blunt 
induction of myeloid differentiation of AML1-ETO leukemic cells133. Using the same 
TLE4 knockdown protocol as Kasumi-1 cells, I found knockdown of TLE4 was able to 
decrease CD14+ populations in HL60 cells and reduce PU.1 and MYB expression (Figure 
3). qRT-PCR assays using RNA from T4KD and control Kasumi-1 cells revealed 
decreased expression levels of select myeloid transcription factors and markers (Figure 
13). While expressed during most phases of myelopoiesis, PU.1 is a master regulator of 
early myelopoiesis that is required for myeloid progenitor differentiation134,135. In fact, 
ectopic expression of PU.1 was able to induce myeloid reprogramming of primary B-cell 
leukemia cells into CD14+ macrophage-like cells136. MYB has been shown to play an 
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integral role in promyelocytic differentiation and is most abundantly found in immature 
myeloblast populations135. ELANE and MPO, neutrophil elastase and myeloperoxidase, 
respectively, are two commonly used markers to identify early neutrophil differentiation 
and committed myeloblasts7. Work pursued by Dr. Farshid Dayyani and myself have 
demonstrated similar trends in T4KD-induced inhibition of CD14+ induction and 
myeloid transcription factor expression in HL60 cells, suggesting that TLE4 regulates the 
induced differentiation potential of myeloid leukemic cells (data not shown). 
 Previous studies using Tle4 knockout mice have shown loss of Tle4 impairs 
maintenance and viability of HSCs in murine hematopoiesis113. This negative effect on 
normal HSCs seemed in apparent contrast to our postulated positive effect of TLE4 loss 
on t(8;21) leukemic cells. To explore this further, I used conditional Tle knockout mice 
that have been developed in our laboratory113. These mice have LoxP excision site 
insertions flanking exon 2 of Tle1 and Tle4 (T14F). Excision of this exon leads to a 
truncated transcript with an early stop codon and interferes with normal Q domain 
activity, a region responsible for tetramerization of TLE and its subsequent normal 
function113,115. Conditional knockout mice have Cre recombinase insertions following the 
Mx1 promoter, allowing for specific knockout of Tle in Mx1-expressing cells (T14F cre). 
The myxovirus resistance-1 promoter, Mx1, is responsive to interferon-γ signaling by 
pIpC injections and has been used in similar Cre-Lox systems to target inducible 
knockout in hematopoietic and bone marrow stroma compartments43,129. Lineage-
negative hematopoietic cells from T14F or T14F cre mice were retrovirally transduced 
with AML1-ETO and serially replated for CFU assay at 1x103 cells per plate (Figure 4). 
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Similar to the findings with Tle4 null mice, T14F cre colonies, having lost TLE1 and 
TLE4, transfected with control empty vector MSCV-IRES-GFP show significantly 
reduced replating efficiency compared to control. However, the loss of Tle4 in the 
context of AML1-ETO is not deleterious to stem cell viability and replating efficiency. In 
fact, there is a trend towards increased colony size that might have been more significant 
if plated cell count was not equalized at each replating timepoint. Thus, my results were 
consistent with previous observations revealing AML1-ETO is able to immortalize 
replated HSCs despite loss of Tle. 
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Figure 1. shTLE4 decreases message and protein levels of TLE4. (A) qRT-PCR using 
RNA from Kasumi-1 cells treated with two TLE4-specific shRNA confirms knockdown 
of TLE4 message by at least 70% (n=3 biologic triplicates with technical triplicates. *: p 
< 0.05). (B) Western blot confirms decreased TLE4 protein in Kasumi-1 and 293T cells 
treated with shTLE4_2.  
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Figure 2. Kasumi-1 proliferation, apoptosis, and differentiation are sensitive to 
TLE4 expression levels. (A) Cell count of GFP+ Kasumi-1 cells treated with scramble 
control or TLE4-specific shRNA coexpressed with IRES-GFP in lentivirus were tracked 
over 18 days (statistics for exponential growth curve k compared to control). (B) 
Similarly treated cells were fixed and stained with for DAPI cell cycle or (C) stained for 
Annexin V analysis 7 days post-lentiviral infection. Dead population was defined as 
Annexin V+ and DAPI+ cells. (D) qRT-PCR query of two repressive targets of AML1-
ETO, CEBPb and GATA1, reveal decreased levels of expression in TLE4 knockdown 
Kasumi-1 cells. (E) Flow cytometry shows percentage of control and T4KD GFP+ cells 
that are CD14+ after culture in media supplemented with DMSO or 10uM ATRA. (All 
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experiments carried out in biologic triplicates and repeated at least twice with technical 
triplicates. D and E: T4KD achieved using shTLE4_2, *: p < 0.05, **: p < 0.01)  
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Figure 3. T4KD suppresses myeloid transcription factor expression and blocks 
pharmacologically induced CD14 presentation in HL60 cells. (A) HL60 cells treated 
with shTLE4 or control shRNA were analyzed by flow cytometry seven days post-
spinoculation without Vitamin D3 treatment to observe changes in CD14+ populations 
and (B) subsequently sorted for qRT-PCR to query for myeloid transcription factors. (All 
experiments carried out in biologic and technical triplicates. T4KD achieved using 
shTLE4_2, *: p < 0.05, ***: p < 0.001, ****: p < 0.0001) 
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Figure 4. Effects of loss of Tle1 and Tle4 in hematopoietic stem cell populations are 
context-dependent. Schematic diagram summarizing procedure for bone marrow harvest 
from inducible Tle1/Tle4 knockout mice, transduction with MSCV-IRES-GFP or MSCV-
AML1-ETO-IRES-GFP, and serial replating in methylcellulose culture. Graph depicts 
colony forming units (CFU) manually counted per 35mm2 plate for three successive 
weeks. (n=2 biologic replicates with technical quadruplicates. *: p < 0.05, **: p < 0.01)  
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TLE4 knockdown upregulates immune and inflammatory pathways in t(8;21) leukemic 
cells 
 To better understand the mechanism behind the oncogenic effects of T4KD, RNA 
from Kasumi-1 cells seven days after lentiviral delivery of control or TLE4-specific 
shRNA were used for 50bp paired-end RNAseq analysis. Results are summarized in a 
heatmap (Figure 5A) and were verified by querying select genes with log2 fold change 
greater than 0.5 and false discovery rate (FDR) of less than 0.2 via qRT-PCR using RNA 
harvested from an independent experiment (Figure 5B). After filtering differentially 
expressed genes for FDR < 0.2, Gene Set Enrichment Analysis (GSEA) analysis using 
the upregulated geneset showed enrichment of immune and inflammation-related 
pathways (Figure 5C). Within this filtered upregulated geneset, a number of genes were 
identified as mediators of immune responses and inflammation in cancer. These genes 
included PTGER4, FOS, CEBPB, and IL1B. PTGER4, one of the two major 
prostaglandin receptors responsible for mediating intracellular inflammatory signals after 
arachidonic acid metabolism by COX, and FOS, a critical component of the AP-1 
complex, have been increasingly studied in the context of cancer and angiogenesis88,137-
139. C/EBPβ, a member of the CAAAT/Enhancer-Binding Protein family, has been 
implicated as a major mediator of IFNγ response and inflammation140-142. IL-1β is an 
inflammatory cytokine that is regulated by various signaling pathways and gatekeepers, 
including those transcription factors C/EBPβ and FOS140,141. Additionally, these genes, in 
addition to other significantly upregulated genes, were found in the leading edge of a 
geneset that is upregulated in AML1-ETO expressing monocytes described by Tonks and 
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colleagues, further suggesting the contribution of TLE4 knockdown enhancing AML1-
ETO function143. These results were particularly interesting given that previous studies 
have shown the role of these genes in mediating COX-dependent inflammation, an 
increasingly studied inflammatory pathway in the context of oncogenesis85-88.   
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Figure 5. RNAseq identifies enrichment of immune system and inflammatory 
response pathways in genes upregulated in T4KD Kasumi-1 cells. (A) Heatmap 
summarizing differentially expressed genes between T4KD and control Kasumi-1 cells 
(n=2 biologic replicates, T4KD achieved using shTLE4_2, filtered for FDR < 0.2). (B) 
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qRT-PCR verification of select upregulated genes with FDR < 0.2 and log2 fold change > 
0.6 identified from RNAseq (n=3 biologic replicates with technical triplicates, *: p < 
0.05). (C) GSEA plots from analysis identifying pathways enriched in upregulated 
geneset (p and q values obtained from GSEA analysis). 
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Increased inflammation signature due to TLE4 knockdown is mediated through interplay 
between TLE4 and COX-Wnt signaling axis 
 Previous work by Zhang et al described how AML1-ETO drives upregulation of 
COX, contributing to increased β-Catenin stability and activity, possibly through 
inhibition of GSK3β14. Given the known repressive role of TLE4 on Wnt signaling111, 
T4KD would be expected to upregulate and intensify Wnt signaling due to AML1-ETO. I 
hypothesized that the increase of inflammatory gene expression in T4KD Kasumi-1 cells 
are due to this hypothesized increase in Wnt signaling activity.  
I first sought to verify the inflammatory gene upregulation identified by RNAseq 
using qRT-PCR assays. Using samples from shTLE4-treated Kasumi-1 cells seven days 
after knockdown independent from those used for RNAseq, qRT-PCR revealed 
significantly increased expression of COX1 and COX2 as well as of those genes 
associated with prostaglandin metabolism and inflammation identified from above 
RNAseq, including FOS, PTGER4, and CEBPb (Figure 6A). Similar increases in 
inflammatory genes FOS, CEBPb, PTGER4, and IL1b with T4KD were observed in 
HL60 cells, another widely studied myeloid cell line that had previously shown by Dr. 
Farshid Dayyani to have decreased sensitivity to pharmacologic induction of CD14+ 
differentiation with TLE4 knockdown (Figure 6B). Furthermore, qRT-PCR using RNA 
harvested from primary human AML diagnostic bone marrow samples showed higher 
levels of FOS, CEBPb, and PTGER4 expression in del(9q) samples, and even higher in 
those with t(8;21) del(9q), compared to CD34+ controls (Figure 6C). While we cannot 
exclude contributions from other possible mutations in these samples, our findings 
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indicate the potential importance of inflammation in del(9q) and t(8;21) del(9q) myeloid 
leukemia and lends further evidence that increased inflammation may be playing a 
critical role in mediating pro-leukemic characteristics in T4KD Kasumi-1 cells.  
 To further evaluate the role of Wnt signaling in T4KD t(8;21) leukemic cells, I 
first exploited Wnt signaling reporter constructs to obtain relative quantifications of Wnt 
signaling. Kasumi-1 cells were nucleofected with control or TLE4-specific shRNA in 
addition to a TOP-dGFP Wnt signaling reporter construct. GFP mean fluorescence 
intensity (MFI) was significantly higher in T4KD versus control Kasumi-1 cells 24 hours 
post-nucleofection (Figure 7A). As a corollary system, 293T cells were transduced with 
AML1-ETO to better characterize the relationship between TLE4 and the AML1-ETO-
COX-Wnt signaling axis. Ectopic expression of AML1-ETO in 293T cells resulted in 
greater than seven-fold increase in COX1 and COX2 expression as determined by qRT-
PCR (Figure 7B). Work done by Dr. Christopher Brynczka, a colleague in our laboratory, 
had previously described how transduction with AML1-ETO and shRNA knockdown of 
TLE4 are both able to increase Wnt signaling in 293T cells independently. I subsequently 
found that Wnt signaling in AML1-ETO transduced 293T cells increases with T4KD 
compared to control shRNA, further supporting the observation that TLE4 represses Wnt 
signaling in the context of AML1-ETO (Figure 7C).  
To confirm that changes in inflammatory gene expression in T4KD Kasumi-1 
cells were due to increased Wnt signaling, I first sought to verify these genes were bona 
fide Wnt-responsive targets. This was achieved by culturing serum-starved naïve 
Kasumi-1 cells in recombinant human Wnt3a-supplemented media. qRT-PCR analysis of 
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these cells revealed significant increases in expression levels of previously identified as 
Wnt targets144-146, such as LEF1 and CCND3, as well as those previously described in the 
T4KD-associated inflammatory gene signature, such as COX1, COX2, FOS, CEBPb, and 
PTGER4 (Figure 8). These findings verified that TLE4 knockdown in Kasumi-1 cells 
resulted in increased Wnt signaling and the inflammatory gene signature identified by 
RNAseq is Wnt-responsive.	
 I next sought to verify that the upregulated genes and proliferative advantage due 
to T4KD were in fact dependent on resultant deregulation of Wnt signaling. T4KD and 
control Kasumi-1 cells were cultured in media supplemented with 10uM ICG-001, a 
small molecule inhibitor that binds with CBP to block b-Catenin/TCF-mediated Wnt 
signaling72,111,147-149. Activating interactions between CBP, p300, β-Catenin, and TCF 
require clearance of TLE/TCF binding111, which makes ICG-001 a suitable inhibitor of 
T4KD-mediated Wnt signaling activation. Fold change of GFP+ lentiviral treated T4KD 
and control Kasumi-1 cells significantly diminished over 15 days in presence of ICG-001 
(Figure 9A). qRT-PCR analysis further demonstrated that ICG-001-mediated Wnt 
inhibition was able to abrogate expression of not only COX1 and COX2, but also the 
aforementioned inflammation and Wnt target genes (Figure 9B). These results suggest 
that, while COX inhibition does indeed block Wnt signaling and consequent upregulation 
of inflammatory genes, the effects mediated by T4KD are largely dependent on release of 
Wnt regulation.  
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Figure 6. T4KD induced expression of inflammatory genes is mirrored in primary 
human leukemia samples. qRT-PCR using RNA harvested from (A) Kasumi-1 cells 
and (B) HL60 cells seven days after lentiviral T4KD reveals increases in COX1, COX2, 
and inflammatory genes related to prostaglandin metabolism and downstream mediators. 
(C) Flow cytometry analysis of GFP MFI reveals increased Wnt signaling activity in 
Kasumi-1 cells nucleoporated with TLE4-specific shRNA and TOPdGFP reporter 
construct. (A-B: n=3 biologic replicates with technical triplicates. C: n=10-12 biologic 
replicates with technical triplicates per arm. T4KD achieved using shTLE4_2 in A and B, 
*: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001)  
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Figure 7. T4KD induces increased Wnt signaling in Kasumi-1 and AML1-ETO-
expressing 293T cells. (A) Flow cytometry analysis of GFP MFI reveals increased Wnt 
signaling activity in Kasumi-1 cells nucleoporated with TLE4-specific shRNA and 
TOPdGFP reporter construct. (B) qRT-PCR using RNA from AML1-ETO expressing 
293T cells shows significant increases in COX1 and COX2 expression compared to 
control naive 293T cells (n=3 biologic triplicates with technical triplicates. *: p < 0.05, 
**: p < 0.01). (C) TOP/FOP ratios were calculated using firefly and renilla luciferase 
activity of 293T cells 48 hours after nucleoporation with TOPFlash/FOPFlash reporter 
constructs, AML1-ETO expression vector, and either control or TLE4-specific shRNA. 
Assay reveals increased Wnt signaling activity in T4KD 293T cells compared to control, 
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which is reversed by addition of 50uM indomethacin in culture media. (n=3 biologic 
replicates with technical triplicates. T4KD achieved using shTLE4_2 in A and C, *: p < 
0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001) 
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Figure 8. Select genes are confirmed as Wnt targets. qRT-PCR with probes for 
inflammatory genes identified by RNAseq and other Wnt targets was performed using 
RNA harvested from Kasumi-1 cells cultured in media supplemented with either 10nM 
recombinant human Wnt3a or DMSO. Assays confirm that queried genes are sensitive to 
presence of rhWnt3a, suggesting they are targets of Wnt signaling. (n=3 biologic 
triplicates with technical triplicates. *: p < 0.05, **: p < 0.01) 
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Figure 9. Wnt inhibitor ICG-001 is able to suppress T4KD-induced cell growth and 
expression of inflammatory genes and Wnt targets. (A) Kasumi-1 cells treated with 
lentiviral TLE4-specific or control shRNA delivery were tracked for fold change in GFP+ 
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cells in the presence of either 10nM ICG-001 or DMSO. While T4KD confers increased 
cell proliferation, ICG-001 is able to stunt growth of Kasumi-1 cells regardless of TLE4 
status (n=3 biologic replicates; T4KD achieved using shTLE4_2, statistics for 
exponential growth curve k compared to control + DMSO arm). (B) RNA from 
aforementioned cells was harvested at day 15 of culture for qRT-PCR. Assays reveal 
ICG-001 is able to reverse T4KD-induced increases in inflammatory and Wnt target gene 
expression. (n=3 biologic replicates with technical triplicates, T4KD achieved using 
shTLE4_2) 
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Cyclooxygenase inhibition by indomethacin reverses TLE4 knockdown-induced cell 
proliferation and drug resistance in t(8;21) leukemic cells 
 While the inhibition of Wnt signaling was able to abrogate T4KD pro-leukemic 
effects in Kasumi-1 cells, Wnt signaling is a critical mediator of normal tissue 
development and cell function150. Thus, Wnt signaling blockade presents itself as a 
dangerous venture as the intervention could have significant undesired toxicities. While 
ICG-001 provided insight into the effects of Wnt inhibition in T4KD Kasumi-1 cells, it 
remains an investigational drug that has been investigated to date only in select pre-
clinical studies147,151. As an alternative, increasing amount of interest has grown in 
understanding how non-specific Wnt signaling antagonists may affect Wnt signaling in 
various disease models, especially in colon and breast cancer models50. One of such 
drugs that are currently clinically available are non-steroidal anti-inflammatory drugs 
(NSAIDs), including COX inhibitors. Indomethacin (INDM) is a non-selective COX 
inhibitor that has previously been used as a clinically available inhibitor of Wnt signaling 
in models of myeloid leukemia14. Adding 50uM indomethacin (INDM) was able to 
significantly reduce TOPFlash luciferase activity, a reporter of Wnt signaling, compared 
to DMSO control; consistent with prior work describing the role of COX regulation of 
Wnt signaling. (Figure 7C)  
 I next sought to determine the efficacy of COX inhibition in reversing the effect 
of T4KD. Kasumi-1 cells treated with control or TLE4-specific shRNA were cultured in 
50uM INDM for 16 days (Figure 10A). COX inhibition was able to significantly reduce 
growth of T4KD cells compared to DMSO control by four days. By day 13, growth of 
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INDM-treated T4KD Kasumi-1 cells plateaued and fell below that of control cells.  
Previous reports have associated the additional finding of del(9q) with decreased survival 
rates in t(8;21) AML. In contrast to t(8;21), which carries a relatively good prognosis, 
del(9q) by itself is considered an intermediate-risk prognostic factor152,153.In light of these 
findings, I sought to examine how the loss of TLE4 affects response to chemotherapy. 
Kasumi-1 cells subject to T4KD or control cells were similarly treated Kasumi-1 cells 
were cultured in 100uM cytarabine (AraC), a conventional chemotherapy agent at an 
amount equivalent to serum concentrations in patients undergoing high-dose therapy154. I 
found that T4KD conferred a relative resistance to AraC treatment, indicated by 
significantly reduced dead cell populations (Figure 10B). Interestingly, the addition of 
INDM was able to overcome T4KD-induced AraC resistance and resulted in even higher 
levels of cell death compared to control, pointing to the potential use of INDM as 
adjuvant therapy for conventional chemotherapeutics.  
 Furthermore, qRT-PCR assays demonstrate significant upregulation of Wnt 
targets, including LEF1 and CCND3, in Kasumi-1 and 293T cells treated with TLE4-
specific shRNA compared control, which can be partly reversed with the addition of 
INDM (Figures 11 and 12). These effects were also seen with the previously described 
mediators of COX inflammation identified by RNAseq. We used qRT-PCR assays to 
query changes in expression levels of the previously described myeloid transcription 
factors and differentiation markers in Kasumi-1 cells due to T4KD and INDM treatment. 
We found the expression levels of ELANE, MPO, and PU.1 were significantly repressed 
in T4KD Kasumi-1 cells (Figure 13) consistent with inhibition of differentiation. INDM 
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was able to significantly increase expression of these genes, suggesting that COX 
inhibition may relieve the block in differentiation due to T4KD. However, INDM 
treatment alone was ineffective in causing significant differences in CD14+ populations. 
We were interested in determining whether adding INDM to ATRA might lead to 
increased differentiation. However, the effects of combination ATRA and INDM therapy 
potently caused leukemic cell death preventing analysis of the effect on CD14 
presentation. Thus, loss of TLE4 cooperates with AML1-ETO to cause increased 
proliferation, blocked differentiation, and drug resistance through an increase in Wnt-
dependent inflammation mediated by COX activity. We conclude that the interplay 
between TLE4 and the AML1-ETO-COX-Wnt axis underlies the role of TLE4 as a tumor 
suppressor role in AML1-ETO leukemia (Figure 14).  	  
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Figure 10. Indomethacin is able to reverse cell proliferation and drug resistance due 
to T4KD in Kasumi-1 cells. (A) T4KD and control Kasumi-1 cells were tracked for fold 
change in GFP+ cells in the presence of either 50uM INDM or DMSO. Presence of 
INDM is able to stunt T4KD-induced cell growth (n=3 biologic replicates; T4KD 
achieved using shTLE4_2, statistics for exponential growth curve k compared to control 
+ DMSO arm). (B) T4KD and control Kasumi-1 cells were cultured in DMSO, 50uM 
INDM, 100uM araC, or combination of 50uM INDM and 100uM araC. After seven days 
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of treatment, cells were stained for Annexin V analysis and checked for dead GFP+ cell 
populations, which revealed INDM is able to reverse T4KD-induced resistance to araC 
treatment. Dead population was defined as Annexin V+ and DAPI+ cells. (n=3 biologic 
replicates with technical triplicates. *: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 
0.0001) 
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Figure 11. COX inhibition is able to partially reverse T4KD-mediated induction of 
inflammatory genes in Kasumi-1 cells. qRT-PCR was performed using RNA harvested 
from Kasumi-1 cells cultured in media supplemented with either 50uM indomethacin or 
DMSO. Query reaffirms induction of inflammatory genes with T4KD, which is 
abrogated in cells cultured in indomethacin. (n=3 biologic replicates with technical 
triplicates. T4KD achieved using shTLE4_2, *: p < 0.05, **: p < 0.01, ***: p < 0.001, 
****: p < 0.0001)  
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Figure 12. COX inhibition is able to partially reverse T4KD-mediated induction of 
inflammatory genes in AML1-ETO-expressing 293T cells. qRT-PCR was performed 
using RNA harvested from AML1-ETO-expressing 293T cells cultured in media 
supplemented with either 50uM indomethacin or DMSO. Query reaffirms induction of 
inflammatory genes with T4KD, which is abrogated in cells cultured in indomethacin. 
(n=3 biologic replicates with technical triplicates. T4KD achieved using shTLE4_2, *: p 
< 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001)  
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Figure 13. T4KD-induced suppression of myeloid transcription factors is reversible 
by COX inhibition. RNA for qRT-PCR was harvested from Kasumi-1 cells treated with 
50uM INDM or DMSO after lentiviral delivery of shTLE4_2 or control shRNA. Assays 
reveal T4KD-induced suppression of myeloid transcription factors is relieved when cells 
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were cultured in 50uM INDM. (n=3 biologic replicates with technical triplicates. T4KD 
achieved using shTLE4_2, *: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001) 
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Figure 14. Schematic diagram summarizing proposed TLE4 regulation of AML1-
ETO/COX/Wnt axis. TLE4 functions as a gatekeeper of Wnt signaling by regulating b-
Catenin/TCF complex transcriptional activity. By perturbing COX1/2 and b-Catenin/TCF 
complex activity using INDM and ICG-001, respectively, we identify loss of Wnt 
signaling regulation by TLE4 is largely responsible for pro-leukemic phenotype conferred 
by T4KD in t(8;21) leukemia cells.  
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Tle knockout bone marrow transplantation transduced with AML1-ETO fails to produce 
leukemia in recipient mice 
 To further examine the hypothesis of TLE4 functioning as a tumor suppressor in 
AML1-ETO leukemia, I attempted to generate a mouse leukemia model by expressing 
AML1-ETO in bone marrow from conditional Tle4 knockout mice. With help from and 
partnership with Dr. Daniela Krause, we transduced whole bone marrow from conditional 
Tle4 knockout mice with AML1-ETO, AML-ETO9a, or control empty retroviral vector. 
These Tle1 and Tle4 inducible knockout smice were described above. Conditional Tle4 
knockout mice have LoxP sites flanking exon 2 of Tle4 along with insertion of Cre 
recombinase following the Mx1 promoter (T4F cre). Mice without Mx1-cre (T4F) serve 
as a control that does not experience Tle4 exon 2 excision while accounting for any 
effects specific to pIpC treatment. AML-ETO9a is an alternative splice variant of AML1-
ETO found in some human t(8;21) AML and possesses a truncated C-terminus, which has 
been implicated as a potent leukemogenic mutation and generates more virulent 
phenotypes in various human leukemic and mouse HSC cells76-78. Wildtype recipient 
mice were sublethally irradiated and transplanted with donor marrow. By 132 days post-
transplant, recipient mice on all arms of the study were alive. Throughout this time 
period, blood from recipient mice was periodically collected retroorbitally to check for 
changes in composite blood count and GFP+ Gr-1+ cell populations. While there was a 
trend towards recipients of T4F cre marrow transduced with AML-ETO9a having more 
GFP+ Gr-1+ cells, there was no significant difference between treatment and control 
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arms in terms of peripheral blood counts, survival, or GFP+ Gr-1+ cells during this time 
frame (Figure 15).   
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Figure 15. Peripheral blood from recipient mice of leukemia-transduced bone 
marrow shows no leukemia induction by loss of Tle4 and AML1-ETO or AML-
ETO9a alone. Recipient mice were tracked for survival and periodically bled retro-
orbitally for 132 days post-transplant with T4F or T4F cre bone marrow transduced with 
either AML1-ETO or AML-ETO9a co-expressed with IRES-GFP. Percent GFP+ Gr-1+ 
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cells of PBMC were tracked by flow cytometry. (n=8 primary transplant recipient mice 
per arm) 
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Discussion 
 About half of all pediatric AMLs have one of four specific balanced 
translocations that are primary, but insufficient drivers of leukemogenesis64-66,155. The 
most common of these translocations is t(8;21), which creates an AML1-ETO fusion 
gene61,63,105. Our laboratory has previously identified the TLE/Groucho co-repressors as 
apparent gatekeepers preventing leukemia progression of AML1-ETO transformed HSCs.  
 In correlation with previous work showing slower proliferation of AML1-ETO 
expressing leukemia cells with increased TLE4 expression48, I have shown T4KD is able 
to significantly increase growth rate and cell cycling while decreasing cell death. T4KD 
blocked ATRA induction of differentiation as measured by CD14+ expression in 
Kasumi-1 populations. Dr. Farshid Dayyani, a previous member of our laboratory, found 
T4KD was able to inhibit vitamin D3 differentiation of HL60 cells, indicated by reduced 
induction of CD14+ populations (data included in manuscript under review). I have 
found T4KD in HL60 cells decreased expression of myeloid transcription factors and 
increased expression of previously identified inflammatory genes. Together, these 
observations suggest that TLE4 plays a role in regulating the responsiveness of leukemic 
cells to pharmacologic induction of differentiation. We further find that T4KD in 
Kasumi-1 cells decreases CEBPa and GATA1 message, regulators of myeloid and 
erythroid differentiation whose repressed expression serve as proxies of AML1-ETO 
function7,13. Additionally, T4KD conferred resistance to high-dose cytarabine treatment 
in Kasumi-1 cells, consistent with previous reports that associate del(9q) with decreased 
survival and intermediate-risk in t(8;21) patients152,153. Interestingly, inhibition of Wnt 
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signaling by INDM was able to reverse the T4KD-induced resistance to cytarabine – 
implicating upregulation of Wnt signaling by T4KD is, at least in part, responsible for the 
drug resistance seen in T4KD cells. These observations indicate TLE4 appears to function 
as a tumor suppressor, whose absence confers pro-survival and blocked differentiation in 
t(8;21)-harboring leukemia. Expression analyses indicate T4KD-induced growth is 
concomitant with upregulation of pathways related to inflammation and immune 
responses. This is consistent with previous studies that propose AML1-ETO-dependent 
survival of leukemic cells is dependent on a COX/b-Catenin axis14. T4KD leads to 
significant upregulation of COX1, COX2, and select inflammatory genes related to 
prostaglandin metabolism; implicating TLE4 as an important regulator of the relationship 
between AML1-ETO, COX, and b-Catenin (Figure 14).  
 The synergy between AML1-ETO and loss of TLE4 is further evidenced by the 
immortalization of Tle knockout colonies via transduced AML1-ETO expression. Studies 
using T4KO mice have demonstrated the detrimental effect of Tle4 knockout in normal 
mouse bone development and hematopoiesis, where Tle4 null mice displayed severe bone 
mineralization defects and intrinsic and extrinsic effects on hematopoietic stem cell 
maintenance113. While the extrinsic effects of Tle4 knockout in the bone marrow niche on 
leukemic cells was not examined, our experiments demonstrate Tle4 loss in the context of 
AML1-ETO expression has intrinsic pro-oncogenic effects on leukemic stem cell 
propagation and survival. This is consistent with previous observations, where many 
t(8;21) patients with detectable AML1-ETO in blood spot samples at birth do not develop 
myeloid leukemia for up to 10 years later in life after a concomitant, synergistic “second 
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hit” mutation48,49,110. Some patients have subpopulations of t(8;21) leukemic cells with 
and without del(9q), indicating del(9q) can develop as a second hit. These results suggest 
loss of the TLE4 AML tumor suppressor gene may be a transforming event in pre-
leukemic AML1-ETO expressing cells that result in the leukemic proliferation of 
immature myeloid blasts.  
 Interestingly, preliminary experiments using transplantation of Tle4 knockout 
bone marrow transduced with AML1-ETO or AML-ETO9a were unable to induce frank 
leukemia in wild-type mouse recipients within a 4-month period. This may represent the 
need for additional cooperating leukemic cell mutations or failed engraftment into a 
suboptimal niche. Recent developments have described the critical role of inflammation 
and cytokine signaling by leukemic myeloid cells on bone marrow niche remodeling and 
subsequent leukemia development32. Work by others in our laboratory has determined 
that loss of Tle1 confers a pro-inflammatory state in the bone marrow niche and other 
tissues that facilitates tumor engraftment and growth96. Having identified the association 
between T4KD, proliferation, and inflammation in Kasumi-1 cells, future investigations 
into how TLE4 regulation of inflammation exerts intrinsic and extrinsic influences on 
leukemic stem cells in the bone marrow may drive leukemia development are warranted. 
 Wnt signaling has been extensively studied in the context of various malignances, 
including colon cancer, as a key regulator of cancer cell proliferation and survival144,156. 
Consistent with the known repressor function of TLE4 on TCF/LEF activity111,157, we 
demonstrate that T4KD increases Wnt signaling and Wnt-responsive gene expression in 
Kasumi-1 and AML1-ETO-expressing 293T cells, with simultaneous upregulation of a 
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pro-inflammatory signature. T4KD-induced upregulation of these inflammatory Wnt 
targets are partially reversible by INDM, suggesting that the other inflammatory genes 
are downstream of both COX and Wnt signaling. Interestingly, the repression of one of 
these targets, CCND3, is thought to be responsible for growth suppression in AML1-ETO 
expressing cells and release of such repression has been associated with proliferative 
leukemia, especially in the AML-ETO9a model158-160.  
The contributing role of TLE co-repressors as regulators of other pro-
inflammatory pathways, including NFkB activation, cannot be excluded. However, the 
importance of Wnt signaling on Kasumi-1 growth and AML1-ETO function is 
emphasized by the extreme lethality of ICG-001, which repressed growth of Kasumi-1 
cells regardless of TLE4 status. ICG-001 was able to block the induction of COX1 and 
COX2 as well as other inflammation-related gene expression due to T4KD. Decreased 
Wnt signaling and target gene expression due to INDM was correlated with reduced cell 
proliferation and increased sensitivity to AraC treatment; indicating anti-inflammatory 
interventions can reverse the pro-leukemic effects of T4KD in t(8;21) AML cells. While 
INDM treatment alone was insufficient to induce any significant differences in CD14+ 
populations, combining ATRA or Vitamin D3 with INDM was extremely lethal and left 
no viable cell populations for meaningful analysis; warranting additional studies to 
investigate potential of ATRA/Vitamin D3 and INDM combination therapy. 
Interestingly, Wnt signaling regulates hematopoiesis and its aberrant constitutive 
activation has been associated with defective hematopoietic stem cell maintenance and 
differentiation10,159. qRT-PCR analysis showed significant decreases in PU.1, MPO, and 
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ELANE expression in T4KD Kasumi-1 cells that are subsequently reversed by INDM; 
reinforcing the relationship between T4KD-mediated pro-leukemic effects, inflammation, 
and Wnt signaling. Based on these results, inflammatory gene signatures deserve further 
investigation as a potential biomarker for COX inhibition sensitivity in de novo myeloid 
leukemia. The demonstration that COX inhibition is able to reverse the pro-leukemic 
phenotype due to T4KD points towards a potential novel therapeutic approach for 
myeloid leukemia. This provides further confidence that the relationship between TLE4, 
Wnt signaling, and downstream inflammation targets is integral to the role of TLE4 as a 
tumor suppressor in Kasumi-1 cells. 
 
Experiment limitations 
 The work described here elucidates a novel AML tumor suppressor role of TLE4 
as an important regulator of AML1-ETO-induced Wnt signaling and inflammation. 
However, our findings have been described primarily in human leukemic cell line models 
that harbor additional mutations and other abnormalities that may influence the activity of 
TLE4, AML1-ETO, and Wnt signaling. It would be of great interest to pursue similar 
experiments using primary AML1-ETO human samples to study the role of TLE4 loss in 
a model with greater fidelity. This was not possible due to limited resources to obtain 
viable cells and relative scarcity of t(8;21) samples. Nonetheless, our experiments have 
shown a novel relationship between TLE4 and inflammation that has never been 
characterized before. Additional studies into how TLE4 directly affects AML1-ETO 
function and regulates mediators of inflammation are warranted. Our results do not 
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distinguish TLE4 acting on downstream targets of AML1-ETO versus directly binding to 
and inhibiting the function of AML1-ETO. Using co-immunoprecipitation, we have 
previously shown potential direct binding between TLE4 and AML1-ETO48. 
Additionally, given the canonically described function of TLE as a co-repressor, it is 
indeed possible that secondary indirect effects of T4KD on AML1-ETO and downstream 
targets are responsible for the pro-leukemic phenotype rather than TLE-direct effects. To 
distinguish between these possibilities, ChIPseq could be used to directly map TLE4 and 
AML1-ETO binding sites. My preliminary attempt at these experiments using TLE4 
knockdown Kasumi-1 cells in collaboration with Mr. Joel Cottom and the laboratory of 
Dr. Bradley Bernstein was unsuccessful due to sub-optimal anti-TLE4 antibodies. Our 
laboratory is continuing to fine-tune the anti-TLE4 ChIP for future studies. 
 Given the striking results from our in vitro experiments, I had made a preliminary 
attempt at generating a mouse leukemia model using the conditional Tle4 knockout 
mouse model. Transplantation of conditional Tle4 knockout bone marrow transduced 
with AML1-ETO or AML-ETO9a failed to generate leukemia in primary recipient wild-
type mice. However, these results do not necessarily conclude that loss of Tle4 is not 
cooperative with mouse models of AML. The knockout efficiency post-pIpC treatment 
was not quantified during this experiment; thus, it is possible that leukemia did not fully 
develop due to incomplete or inefficient Tle4 excision. These results may reflect 
inefficient AML1-ETO transduction of stem cells or lack of sufficient stem cell 
reprogramming by AML1-ETO before the introduction of Tle4 excision. At the same 
time, it may also be evidence to suggest that, in murine models of leukemia, additional 
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factors besides loss of Tle4 and AML1-ETO expression are required for leukemogenesis. 
Additional characterization of the T4F and T4F cre mice may provide greater insight into 
whether post-natal induction of Tle4 knockout is able to replicate phenotypes similar to 
the T4KO mouse model. These new findings may shed light on the importance of the 
timing of Tle4 excision and its potential relevance to AML1-ETO leukemogenesis. 
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CHAPTER FOUR: Tle4 PLAYS A CRITICAL ROLE IN REGULATING 
HEMATOPOIETIC STEM CELL MAINTENANCE AND BONE 
DEVELOPMENT 
 Parts of this chapter were originally published in: Wheat JC*, Krause DS*, Shin 
TH*, Chen X, Wang J, Ding D et al. The corepressor Tle4 is a novel regulator of murine 
hematopoiesis and bone development. PLoS ONE 2014; 9: e105557. 
 
Rationale 
 While we have identified and characterized the role of TLE4 as a tumor 
suppressor in AML, very little is known about its role in mammalian development. Our 
laboratory had previously developed a novel Tle4 null mouse to explore the role of Tle4 
in hematopoiesis. I have contributed to this effort by pursuing several studies examining 
whether Tle4 loss affects HSC viability. Our findings revealed that the loss of Tle4 in 
mice has significant stem cell intrinsic and extrinsic effects on hematopoiesis which 
resulted in defective hematopoietic stem cell (HSC) self-renewal and differentiation113. 
Interestingly, we unexpectedly found a severe bone development defect in these mice that 
caused severe runting and decreased bone mineralization113. In this dissertation, I outline 
additional preliminary studies I have pursued to describe how Tle4 loss affects bone 
development and osteoblast function.  
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Results 
Tle4 deficiency causes intrinsic defects in hematopoietic stem cell differentiation and 
viability 
 Experiments performed by Mr. Justin Wheat and members of our laboratory have 
revealed that T4KO mice have significant reductions in LKS and progenitor cell 
populations113. To better understand the significant of Tle4 loss in HSC populations, I 
analyzed LKS cells using cell cycle and apoptosis assays that examine cell proliferation 
and apoptosis respectively. The former experiment revealed no difference in cell 
proliferation and cell cycling between two-week old T4WT and T4KO LKS, as indicated 
by flow cytometry analysis of Ki-67113 (Figure 16A). Interestingly, Annexin V analysis, 
performed jointly by Dr. Daniela Krause and myself, showed LKS cells from two-week 
old T4KO mice exhibiting significantly reduced viability and increased apoptotic and 
dead cells113 (Figure 16B). This suggests the decrease in LKS frequency in T4KO mice 
may be due to Tle4-dependent increased apoptosis rather than changes in cell 
proliferation or cycling.  
 To further describe the functional effects of Tle4 loss in HSCs, Dr. Daniela 
Krause and I tested the colony-forming ability of sorted LKS cells from two-week old 
T4WT or T4KO mice. After seven days in methylcellulose, T4KO LKS were 
significantly less efficient at forming colonies than T4WT LKS cells, suggesting intrinsic 
HSC defects and impaired HSC self-renewal in T4KO mice113 (Figure 17A). These 
observations were further reinforced by a continued decrease in the ability of T4KO LKS 
cells to produce colonies when serially replated in methylcellulose at 14 days113 (Figure 
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18B). Methylcellulose culture, a semi-solid growth medium supplemented with growth 
factors and cytokines, allow LKS cells to divide and differentiate in close proximity and 
form clusters or colonies of cells. These colonies can be typified by morphology as 
granulocyte/macrophage-forming (CFU-GM), erythroid-forming (BFU-E), or 
granulocyte/erythrocyte/mono-cyte/megakaryocyte-forming (CFU-GEMM) colony 
forming units to identify any Tle4-dependent HSC-intrinsic effects on progenitor 
differentiation. After 13 days in methylcellulose culture, sorted LKS cells from T4KO 
were less efficient in forming CFU-GM and CFU-GEMM compared to their T4WT 
counterparts113 (Figure 17C). To further test these effects, my colleague Mr. Justin Wheat 
performed primary transplantations of two-week old T4KO bone marrow and serial 
transplantation of E13.5 T4KO fetal liver cells into WT recipients113. These experiments 
demonstrated that recipients of T4KO HSC developed leukocytopenia, lymphopenia, and 
aberrant B-cell development. Thus, our experiments demonstrate loss of Tle4 causes 
intrinsic defects in HSC differentiation and self-renewal capacities.  
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Figure 16. The decrease in LKS cells in Tle4 null mice is due to proliferation and is 
accompanied by abnormalities of the bone marrow stroma. (A) LKS cells isolated from 
two-week old T4WT and T4KO littermates show no difference in cell cycle distribution 
measured by Ki-67 flow cytometric analysis. (B) Annexin V analysis of the same cells, 
however, shows an increase in apoptotic and dead populations in T4KO LKS cells 
compared to T4WT. (n=3 biologic replicates per arm; *: p < 0.05, **: p < 0.01, ***: p < 
0.001) 
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Figure 17. LKS cells from T4KO mice are impaired in colony forming unit ability 
compared to T4WT littermates. Methylcellulose CFU assays show decreased number 
of colonies originating from 1x103 T4KO LKS cells compared to T4WT on (A) day 7 
and again after replating on (B) day 14. (n = 4 biological replicates per arm, technical 
triplicates; **: p < 0.01, ***: p < 0.001) (C) LKS cells from T4KO mice form fewer 
CFU-GM and CFU-GEMM colonies but similar BFU-E colonies compared to T4WT. (n 
= 5 biological replicates per arm, technical triplicates; p < 0.01, ***: p < 0.001)  
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Loss of Tle4 causes defects in bone mineralization, metabolism, and formation 
 Preliminary studies performed by our laboratory have revealed T4KO mice, while 
grossly normal at birth, are severely runted and expire by three weeks of life. These 
findings were associated with defective bone mineralization, measured by Alizarin 
Red/Alcian Blue staining of skeletons and von Kossa staining of femurs from one-day 
old T4KO and T4WT littermates113 (Figure 18A and B). I examined three-week old 
T4KO and WT femur sections for tartrate-resistant acid phosphate (TRAP) staining, a 
commonly used enzymatic histology assay used to identify osteoclasts. TRAP staining 
found increased aggregation of osteoclasts in the hypertrophic zones near the bone 
marrow cavity border and under growth plates of T4KO mice compared to T4WT, which 
may contribute to trabecular bone resoprtion113 (Figure 18C). Expression levels of other 
Tle family members did not significantly differ between T4WT and T4KO mice, 
confirmed by qRT-PCR (Figure 18D). 
 Based on these findings indicating developmental defects in the skeletal system of 
Tle4 null animals, I undertook comparisons of bone formation in T4KO versus T4WT 
mice. In collaboration with Dr. Cathy Raggio, I submitted three-day old T4KO and 
T4WT littermates for microCT analysis of bone volumes. Bone volume fraction (BVF) 
measurements show T4KO littermates had decreased mineralized bone, consistent with 
previous mineralization assays (Figure 19A). Additional microCT measurements show 
decreased spinal canal AP diameters in L2 and L3 vertebrae of T4KO mice, suggesting 
T4KO have shorter vertebral pedicle length (Figure 19B). Femurs were also collected 
from eight to nine-day old T4KO and WT littermates for trabecular and medullary bone 
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volume measurements by the microCT core at the Harvard School of Dental Medicine. 
While analysis was unable to produce trabecular values due to lack of sufficient 
trabecular bone, medullary bone volumes and cortical thickness were both lower in 
T4KO mice compared to their T4WT littermates (Figure 20). While the analyses did not 
reach statistical significance, most T4KO samples clustered close to the mean with 
minimal variance with the exception of one outlier mouse that was consistently above 
one standard deviation from the mean. Excluding this mouse, differences in cortical 
thickness measurements reach statistical significance at p = 0.02. Additional analysis of 
three to four-week old T4KO mice, however, produced microCT images of vertebral 
trabeculae qualitatively demonstrating decreased bone and increased trabecular space 
(Figure 19C). In support of the importance of TLE4 in bone development, a TLE4 
missense mutation has been identified by our collaborators as a strong candidate gene in a 
family with congenital vertebral malformations, osteopenia, and open anterior skull 
fontanelle161. 
 While we confirmed loss of Tle4 affects bone development, I sought to determine 
dynamic measurements of bone formation to further characterize Tle4 regulation of bone 
formation. After consultation with Dr. Nicolas Severe and the MGH Bone Endocrine 
Histomorphometry Core, I designed a mineral apposition assay using conditional Tle4 
knockout mice. Mineral apposition assays provide dynamic measurements of bone 
formation, including mineral apposition rates (MAR), a measure of how quickly 
osteoblasts are forming and mineralizing new bone, and bone formation rate (BFR), a 
composite measurement of how quickly bone is forming. For these experiments I utilized 
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tissue specific conditional Tle4 knockout mice to circumvent difficulties related to short 
lifespan of T4KO mice and isolate effects of T4KO in newly developing and maturing 
osteoblasts from influences due to the hematopoietic compartment. As described in the 
previous chapter, these conditional Tle4 knockout mice express Cre recombinase under 
the control of the Mx1 promoter, which is responsive to interferon-γ signaling induced by 
pIpC treatment. Treatment of these mice with pIpC results in inactivation of the Tle4 
gene in hematopoietic cells as well as cells of the bone marrow stroma. A previous study 
by Park et al has shown that Mx1-expressing members of the bone marrow stroma are 
responsible for the generation of new osteoblasts in mice129.  
The MAR assay revealed T4F cre mice have lower MAR and BFR (Figure 21A 
and B). MAR and BFR rates in T4F cre mice had very small variation while one outlier 
T4F mouse consistently showed MAR and BFR rates below the mean by over one 
standard deviation. Analyses of MAR rates excluding this outlier mouse show 
statistically significant decreased MAR in T4F cre mice at p < 0.05. Additionally, T4F 
cre mice had lower osteoblast number to bone perimeter ratios (N.Ob/B.Pm) which 
suggested less number of osteoblasts per given area of bone (Figure 21C). Trichrome 
staining of the same samples further showed that T4F cre mice had significantly lower 
OS/BS values, a ratio of osteoid to bone surface area (Figure 21D). Osteoid is 
unmineralized bone matrix comprised of collagen, osteocalcin, and chondroitin sulfate 
that is initially laid by osteoblasts in bone formation26,28,29. While these values seem to 
suggest Tle4 loss is associated with decreased bone formation, other values seem to 
suggest T4F cre mice having more osteoblast activity. Using BV/TV as a static 
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measurement estimating bone volume, T4F cre mice had significantly higher bone 
(Figure 21E). Moreover, T4F cre mice had decreased mineralization lag times, a value 
that uses osteoid thickness and mineral apposition rates to estimate an interval between 
osteoid deposition and mineralization. However, conditional Tle4 excision occurred 
within two weeks of demeclocycline and calcein pulses used to measure dynamic 
parameters of the MAR assay. Of note, these values heavily depend on long-term bone 
development that goes beyond the scope of the MAR assay. As suggested by Park and 
colleagues, osteoblast turnover is approximately 30 days, suggesting that large 
discrepancies in bone volume and osteoid thickness may be a result of a longer-term 
process exogenous of the two week Tle4 excision timeframe129. Thus, the MAR assay 
results suggest that loss of Tle4 disrupts normal bone formation and mineralization, 
possibly due to decreased osteoblast number, function, or both. Interestingly, bone slides 
used for trichrome staining showed a qualitatively higher amount of bone marrow fat in 
T4F mice compared to T4F cre. Increased adipogenesis by bone marrow stromal cells has 
been frequently described after radiation treatment by previous reports162,163. These 
results suggest that Tle4 loss in the bone marrow stroma may contribute towards 
osteoblast and bone marrow stroma protection against radiation-induced bone marrow 
adipogenesis.  
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Figure 18. Tle4 null mice exhibit growth retardation and under-mineralization of 
bone. (A) Alizarin Red/Alcian Blue staining for ossified bone (red) and cartilage (blue) 
of one day old T4WT and T4KO skeletons shows decreased mineralization in Tle4 null 
mice of both membranous bone (skull) and endochondral bone (vertebrae and long 
bones). (B) One day old T4KO mice have decreased mineralization of the trabeculae and 
cortical bone in the tibiae compared to T4WT littermates as shown by Von Kossa 
staining. (C) Tartrate-resistant acid phosphatase (TRAP) staining (pink) demonstrates 
osteoclasts clustering under the hypertrophic zone at the boundary of the bone marrow 
cavity in Tle4 null mice at 3 weeks of age. (D) Loss of Tle4 does not significantly affect 
the expression of other Tle family members as shown by qRT-PCR of cDNA from the 
bone marrow of two-week old mice. (n=3 biologic triplicates per arm, technical 
triplicates) 
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Figure 19. T4KO mice exhibit decreased bone density and spinal canal diameters in 
L2 and L3 vertebrae at three days of age. MicroCT measurements of (A) BVF and (B) 
AP distance in spinal canal mimic skeletal malformations found in a family with 
congenital vertebral abnormalities due to a putative TLE4 missense mutation. (C) 
MicroCT image reconstructions of trabecular bone in L3 vertebrae of T4WT and T4KO 
mice, illustrating decreased bone density and trabecular bone formation in Tle4 null mice. 
(n=2 biologic duplicates per arm) 
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Figure 20. MicroCT analysis of femurs from T4KO mice further illustrate 
decreased bone formation compared to T4WT littermates. Femurs collected from 
nine-day old T4KO and T4WT littermates were analyzed for (A) medullary bone density 
and (B) cortical thickness. Both measurements show decreased trend in T4KO versus 
T4WT mice. (n=3-4 mice per arm, technical duplicates) 
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Figure 21. MAR assay and trichrome staining results indicate contrasting effects of 
Tle4 loss on bone formation and mineralization. T4F cre mice have decreased (A) 
MAR and (B) BFR rates, measurements of average bone mineralization per osteoblast 
and total bone formation, respectively. (C) T4F cre mice also had less N.Ob/B.Pm values, 
an estimate of the number of osteoblasts per area of bone surface. (D) Trichrome staining 
reveals T4F cre mice have significantly reduced osteoid compared to T4F controls. 
Interestingly, other values derived from these assays suggest that T4F cre have more 
osteoblast activity, measured by (E) increased bone volume and (F) decreased 
mineralization lag time. (F) Moreover, bone sections from T4F cre mice exhibit lower 
amounts of bone marrow fat, suggesting that Tle4 loss conferred protection against bone 
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marrow stromal cell progression to adipocytes due to radiation. (n=3 mice per arm; *: p < 
0.05; **: p < 0.01) 
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Tle4 affects extrinsic regulation of hematopoiesis through its role in bone marrow niche 
maintenance and osteoblast function 
 Given the critical importance of the BM niche on hematopoiesis, we hypothesized 
that the Tle4 knockout-induced abnormalities in the skeletal or stromal compartments of 
the bone marrow were contributing to defective hematopoiesis164,165. Using two-week old 
T4WT and T4KO bone sections, slides of paraffin-embedded humeri were submitted to 
the MGH Histology Core for TUNEL staining, which identifies apoptotic cells113 (Figure 
22A). Compared to T4WT, various compartments of T4KO bone exhibited increased 
TUNEL staining, including the periosteal cells lining lacunae in the epiphysis113 (Figure 
22A, panel C vs. H) and periosteal cells under the cortex of the diaphyseal portion of the 
humerus113 (Figure 22A, panel D vs. I). Moreover, TUNEL staining was more 
extensively pervasive throughout trabeculae and bone marrow in T4KO compared to 
T4WT mice113 (Figure 22A, panel B vs. G, E vs. J). This further suggested the possibility 
that the hematopoietic abnormalities seen in T4KO mice might be at least in part due to 
the absence of support from the osteoblastic niche.  
 To further elucidate whether impaired HSC maintenance by T4KO bone marrow 
was dependent on stromal cell irregularities, Dr. Daniela Krause and I prepared whole 
bone lysates from two-week old T4WT and T4KO mice113. Dr. Krause subsequently used 
the samples for western blotting with antibodies against Scf, a known factor involved in 
the maintenance of HSC21,166. Though some T4KO mice displayed a complete lack of Scf 
expression, others showed modest protein levels (Figure 22B). The considerable animal 
to animal variation suggests that down-regulation of Scf expression is not a direct effect 
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of Tle4 loss, but might reflect a loss of an Scf producing cell type in Tle4 null mice and 
does not preclude the possibility of other factors accounting for the impairment of HSC 
maintenance.  
 Since Tle4 null animals do not survive long enough to serve as bone marrow 
recipients of wild-type HSPC, my colleague Justin Wheat and I adapted a co-culturing 
assay to determine whether HSC-extrinsic factors may have influenced the observed 
hematological phenotype113,130. Mr. Wheat collected wild-type LKS cells from two-week 
old mice and co-cultured them on stromal cells derived from three-day old T4WT or 
T4KO mice for two weeks. Mr. Wheat harvested non-adherent cells and found 6–15% of 
recovered cells from T4WT stromal co-cultures were positive for c-Kit and Sca-1113. In 
stark contrast, Mr. Wheat found less than 1% of cells recovered from T4KO stromal co-
cultures were c-Kit+ Sca-1+113 (Figure 23A). With Mr. Wheat, I similarly set up long-
term co-culture experiments plated in methylcellulose, which revealed an even more 
pronounced effect. Cells recovered from T4WT co-cultures exhibited an average of 10-
fold more colonies than their T4KO counterparts113 (Figure 23B). Some T4KO co-
cultures failed to exhibit any colony forming ability. Thus, Tle4 null stromal cells cannot 
maintain and support HSPC growth as efficiently as T4WT stromal cells.  
 While many different processes and cell types contribute to maintenance of the 
stem cell niche, osteoblasts are thought to be central in regulating HSC development19. 
Given the defective skeletal development and bone mineralization phenotype seen in 
T4KO mice, I hypothesized that loss of Tle4 may affect osteoblast function and 
development. With help from Dr. Daniela Krause, I harvested and flushed femurs from 
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one-week old T4KO and T4WT littermates to isolate RNA from whole bone. These 
samples were used for qRT-PCR querying for various transcription factors involved in 
osteoblast maturation and function. Compared to T4WT littermate bone samples, T4KO 
bone exhibited significantly lower levels of Ap, Runx2, and Oc expression (Figure 24). 
While alkaline phosphatase is often used as a proxy for osteoblast function, Runx2 and 
Oc are intimately tied to normal osteoblast maturation and regulation of bone 
anabolism167. To further characterize osteoblast function, I generated stromal cultures 
derived from culturing crushed one-week old T4KO and T4WT littermates in osteogenic 
media and removing all non-adherent cells. After one week of culture, alkaline 
phosphatase staining showed a qualitative decrease in alkaline phosphatase activity in 
T4KO stromal cultures compared to T4WT (Figure 25A). Stromal cultures were also 
lysed for RNA for qRT-PCR, which demonstrated concomitant decreased levels of 
Runx2, Ap, Oc, and Spp1 expression (Figure 25B).  
 Studies have shown that Runx2 null mice lack ossification of bone and are 
blocked in osteoblast differentiation25. qRT-PCR using T4KO bone and stromal culture 
lysates consistently show decreased Runx2 expression in the absence of Tle4 (Figures 24 
and 25B). To determine whether the defective osteoblast phenotype is consequent of Tle4 
loss or secondary to T4KO-dependent decreased Runx2 expression, I obtained a mouse 
mesenchymal cell line ST2 transformed with a doxycycline-induced expression of Runx2 
(ST2D; Gift of Dr. Baruch Frenkel)27. After Tle4 knockdown and culture in osteogenic 
media with or without doxycycline, ST2D cells were similarly stained for alkaline 
phosphatase activity and lysed for RNA. Qualitatively, there was slightly less alkaline 
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phosphatase staining in Tle4 knockdown ST2D cells compared to control while there was 
no significant difference in cultures grown with doxycycline (Figure 26A). Consistent 
with previous T4KO stromal culture experiments, Tle4 knockdown resulted in decreased 
Runx2 expression in the absence of doxycycline (Figure 26B). Interestingly, while 
doxycycline effectively increased Runx2 expression levels in control cells, the level of 
induced Runx2 expression was impaired by Tle4 knockdown (Figure 26B). Moreover, 
qRT-PCR showed that increases in Oc, Ap, and Osx expression secondary to induced 
Runx2 were consistently less in magnitude in ST2D cells with Tle4 knockdown (Figure 
26C). This suggests that while Tle4 appears to regulate Runx2 expression, it is also 
possible Tle4 may also play a secondary role in supporting Runx2 function and activity in 
osteoblasts.  
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Figure 22. Loss of Tle4 affects bone and periosteal cells within bone marrow niche. 
(A) TUNEL staining of the growth plate of the femur in two-week old mice marks the 
normal zone of cell death between the hypertrophic (H) layer and forming trabecular (T) 
bone (a, b) with an increase in staining in T4KO mice (f, g). Lacunae in the epiphysis are 
lined with periosteal cells undergoing apoptosis in T4KO mice (h), but was not seen in 
T4WT littermates. Similar periosteal cells undergoing apoptosis and stained by TUNEL 
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are seen under the cortex of diaphyseal bone in T4KO mice (i) but absent in wild-type 
mice (d). An increase in TUNEL staining is also observed in cells of the bone marrow in 
T4KO mice (j) as compared to wild-type bone marrow (e). (B) Western blot probing Scf 
protein in flushed bone lysates show modest to reduced levels of Scf in two-week old 
T4KO compared to T4WT littermates. (n=4 biologic replicates; b-Actin used as protein 
loading control) 
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Figure 23. Co-culture of wild-type HSC on T4KO stromal cells impairs long-term 
colony forming ability. (A) Flow cytometric analysis of non-adherent cells from two-
week T4KO stromal co-culture plates show decreased frequency of Sca-1+c-Kit+ cells 
compared to T4WT (n=2 biological replicates per arm, technical triplicates; **: p < 0.01). 
(B) Long term culture-initiating cell assay (LTC-IC) after four weeks of co-culture with 
T4WT or T4KO stroma showed relatively few colonies obtained after culturing on T4KO 
stroma (n = 2 biological replicates, nine technical replicates for co-culture, seeded in 
technical duplicates for CFU; ****: p < 0.0001).  
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Figure 24. Loss of Tle4 affects expression of osteoblast function and differentiation 
regulators. qRT-PCR using RNA from one-week old T4WT and T4KO flushed whole 
bone lysate shows T4KO has decreased expression of Ap, Runx2, and Oc. (n=6 biologic 
replicates, technical triplicates; *: p < 0.05, **: p < 0.01) 
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Figure 25. Stromal cultures derived from one-week old T4KO exhibit defective 
osteoblast phenotypes compared to that of T4WT littermates. (A) T4KO stromal 
culture shows qualitative decreases in alkaline phosphatase activity compared to T4WT 
stromal culture. (n=3 biologic replicates, representative image) (B) Stromal cultures from 
T4WT and T4KO were lysed for qRT-PCR analysis, which shows decreased significantly 
reduced levels of Runx2, Ap, Oc, and Spp1 expression in T4KO compared to T4WT. (n=3 
biologic replicates per arm, technical triplicates; *: p < 0.05, **: p < 0.01, ***: p < 0.001) 
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Figure 26. Tle4 knockdown in ST2D mouse mesenchymal cells mimics aberrant 
osteoblast phenotype seen in cultures derived from T4KO mice. (A) Alkaline 
phosphatase activity is qualitatively decreased in ST2D cells with Tle4 knockdown, 
which is reversed with doxycycline-induced Runx2 expression. (n=3 biologic replicates 
per arm, representative image) (B) qRT-PCR using RNA harvested from Tle4 
knockdown and control ST2D cells confirm effective Tle4 knockdown and Runx2 
induction. (C) However, additional qRT-PCR experiments show induced Runx2 
expression is unable to completely rescue aberrant osteoblast gene repression due to Tle4 
knockdown. 
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Discussion 
 While most of our current understanding of TLE is inferred from observations of 
the Drosophila homologue Groucho, the novel Tle4 null mouse provides valuable insight 
into the previously unappreciated roles of Tle4 in mammalian vertebrates. While the 
complete characterization of this novel mouse was done in partnership with colleagues 
and collaborators, my contribution towards this project describes Tle4 as a regulator of 
bone and hematopoietic development.  
 One of the striking abnormalities in the T4KO mice is a decreased calcification of 
the skeleton. This impaired ossification is apparent in both membranous bone (flat skull 
bones) as well as endochondral bones (long bones) by birth (Figure 16). Combined with 
microCT, MAR assay, and trichrome staining measurements that indicate impaired bone 
formation, mineralization, and osteoid production, these results strongly suggest that Tle4 
may affect osteoblasts and other periosteal cells that are responsible for bone production 
and maintenance. As evident by TRAP staining of femurs from 3-week old T4KO mice, 
we find that loss of Tle4 may impair regulation of osteoclasts. Thus, our observations 
cannot exclude the possibility that Tle4 has a central role in a wide variety of bone cells 
and processes beyond osteoblasts in isolation. Correlations of phenotypes in T4KO mice 
and a family with congenital vertebral abnormalities associated with a missense mutation 
in TLE4 lends further support for identifying Tle4 as intimately tied to maintenance of 
normal bone homeostasis. 
 While our prior experiments have described HSC-intrinsic defects due to Tle4 
loss, the aberrant bone phenotype of T4KO mice prompted questions related to the 
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impact of Tle4 loss on the bone marrow microenvironment. Many reports have described 
the importance of the bone marrow niche in supporting normal hematopoiesis19,21,166. The 
inability of T4KO stromal cultures to maintain wild-type HSC provides evidence that 
aberrant extrinsic regulation of hematopoiesis due to loss of Tle4 in the niche and its 
composite bone cells also contributes to the hematopoietic defects observed in T4KO 
mice. This is further corroborated by TUNEL staining of T4KO bones, which illustrates 
the deleterious and pro-apoptotic effects of Tle4 loss on constituent bone cells in the bone 
marrow niche and stroma. It is important to note that the bone marrow stroma in vivo is a 
complex environment that includes not only osteoblasts, but a wide range of other 
supportive cells, growth factors, and cytokines19,21-24. While culturing mesenchymal cells 
in osteogenic media may push osteoblastic differentiation and development, it does not 
accurately and wholly replicate the natural stromal environment. This difference may 
impact the stromal cultures’ ability to support HSC. Moreover, the established stromal 
cultures were not immunophenotyped to confirm comparable culture conditions between 
the two arms. Western blotting of mouse Scf, a known mediator of HSC maintenance, 
has revealed that constitutive loss of Tle4 in mice leads to dysregulated levels of Scf in 
bone, a major mediator of osteoblast differentiation and maintenance21,166.However, the 
striking differences in HSC viability of cells cultured in T4WT and T4KO stromal 
cultures strongly suggests the likely possibility that loss of Tle4 in the stroma has a HSC-
extrinisic effect on hematopoiesis. 
 Several studies have characterized the importance of osteoblasts in maintaining 
the bone marrow niche and supporting hematopoiesis18,165,168. I have performed 
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preliminary experiments attempting to determine whether the bone abnormalities due to 
loss of Tle4 can be attributable to dysfunctional osteoblasts. Using qRT-PCR analysis of 
lysates prepared from flushed whole bones of and cultured stromal cells derived from 
T4KO mice, I found loss of Tle4 significantly decreased expression of various 
transcription factors and regulators responsible for osteoblast function and differentiation, 
including Ap and Oc – both frequently used proxies for describing osteoblast function. 
Interestingly, osteocalcin is an integral component of osteoid; the decreased expression of 
which may lend insight into a physiologic basis for the Tle4 knockout-induced bone 
phenotype. Moreover, alkaline phosphatase staining qualitatively showed a trend towards 
decreased alkaline phosphatase activity in T4KO stromal cells. These studies were 
corroborated by similar results from repeated assays using a mouse stromal cell line 
ST2D cultured in osteogenic media after Tle4 knockdown.  
 Wnt signaling has been described as a central mediator of bone 
formation25,26,169,170. However, we observed defective bone formation and mineralization 
in T4KO mice, in which Wnt signaling is expected to be activated72,111. However, 
previous studies have shown that there is an intimate relationship between the timing of 
Wnt signaling and normal osteoblast differentiation; and thus, constitutive or increased 
Wnt signaling in an inappropriate stage of osteoblast development can be detrimental to 
normal bone growth169,171. Our results do not preclude the possibility that loss of Tle4 is 
responsible for the bone defects through other mechanisms.  
In addition, qRT-PCR results indicate a decrease in Runx2 expression levels in 
T4KO bone, T4KO stromal cells, and ST2D cells with Tle4 knockdown. Previous studies 
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have shown that TLE proteins are capable of interacting with Runx2, a critical regulator 
of bone development and maturation172,173. Runx2 null mice demonstrate bone 
phenotypes similar, but more severe than our T4KO mouse: expiring at birth and 
completely missing skeletal and bone development, owing to defective osteoblast 
maturation174,175. The less severe effect observed with Tle4 knockout could reflect 
compensatory effects from the expression of other Tle family members. While direct 
interactions between RUNX and TLE have been described demonstrated176, additional 
experiments, such as ChIPseq, may reveal further insight into whether TLE exerts a 
direct regulatory effect on RUNX transcription or RUNX targets. Additional studies are 
required to further characterize the interaction and potential regulatory role of Tle4 on 
Runx2 expression and function, providing an explanation for how loss of Tle4 manifests 
in defective bone development. 
Bone homeostasis also depends on a wide variety of resident bone cells, including 
osteoclasts. Our TRAP staining has suggested an increased number of osteoclasts in the 
trabecular bone of T4KO mice. However, the mechanism underlying this increase in 
osteoclasts remains to be determined. Opg is a critical regulator of osteoclastogenesis by 
serving as a competing receptor for RANKL and downstream activation of 
osteoclasts25,27. While I have found that expression of Opg was not sensitive to Tle4 
levels, it does not preclude that Tle4 may have an osteoclast-intrinsic effect on function, 
recruitment, and activation. 
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Experiment limitations 
 However, we concede that many of our observations are descriptive and require 
additional experiments to understand how Tle4 loss mediates these effects through 
altering regulatory pathways, affecting function of other bone cells, or a combination of 
both. We have attempted to examine mechanism by exploring Scf protein levels in T4KO 
bone. However, the western blot was inconclusive due to a wide variation of Scf protein 
levels among T4KO littermates. However, there is a trend towards decreased Scf 
presence in T4KO samples. It is important to note that the western blot was performed 
using lysate from whole bone after removal of hematopoietic cells by saline flush. Future 
studies could examine whether loss of Tle4 might more specifically impact Scf levels 
within a specific subpopulation of cells in the HSC niche such as osteoblasts.  
 My studies do not preclude the possibility that Tle4 loss may exert a more 
systemic effect on bone development through hormonal and paracrine modulators, such 
as parathyroid hormone levels and calcium metabolism. Previous work has implicated 
Tle1 as a central co-repressor critical to Hesx1-dependent pituitary organogenesis177. 
Additionally, high expression levels of TLE4 have been found in pituitary carcinomas 
and prolactin-secreting pituitary adenomas, suggesting that TLE4 may play a central role 
in regulation of pituitary growth and hormone production178. To address these concerns, I 
have been working with my colleagues in the laboratory to submit peripheral blood 
samples from conditional Tle4 knockout mice to query serum calcium, phosphate, 
vitamin D, and parathyroid hormone levels. While it is uncertain whether Tle4 excision in 
adult mice will impact pituitary function or anatomy, it is possible that it may affect the 
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homeostatic balance of these chemistries and hormones and contribute to the bone 
phenotype that we have observed in our experiments.  
 The current experiments and studies provide insight into a novel regulatory role of 
Tle4 in bone metabolism and lay the foundation for additional investigations to further 
characterize how loss of Tle4 affects bone development. While microCT and histologic 
studies demonstrate T4KO mice have significantly detrimental bone defects, MAR assay 
using adult conditional Tle4 knockout mice create a less clear picture of how loss of Tle4 
affects post-natal bone development. It is particularly important to note that the results 
seen in the MAR assay are generated from experiments that use conditional Tle4 
knockout mice; a different scenario from the Tle4 null mice that have lacked Tle4 from in 
utero. Thus, it is possible that differences seen between the two mouse models can be 
attributed to discrepancies inherent in their Tle4 status and observations made in each 
mouse model do not necessarily contradict each other in describing the role of Tle4 in 
bone development. Moreover, it is possible that different mechanisms exert regulation 
over osteoblast generation versus function in laying new osteoid and mineralizing bone 
matrices; potentially explaining how loss of Tle4 may exert different effects on various 
osteoblast functions. However, it is important to acknowledge that Tle4 was conditionally 
excised in mice within two weeks of measuring MAR with demeclocycline and calcein 
pulses. This suggests that the dynamic parameters of the MAR assay are more reliably 
attributable to effects of Tle4 loss in osteoblasts. The other static parameters, especially 
bone volume, are measurements of longer-term bone development. This is particularly 
supported by previous observations noting osteoblast turnover occurs in approximately 
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30 days129. Thus the significantly higher bone volume in T4F cre versus T4F mice may 
be an animal or litter-specific artifact that is independent from the scope of the MAR 
assay. 
 To further expound on the role of Tle4 on osteoblast development and function, it 
is imperative to pinpoint the exact time and mechanism through which loss of Tle4 
influences osteoblastogenesis. In my MAR studies, I exploited conditional Tle4 knockout 
mice that had an Mx1-inducible Cre recombinase. Mx1 is an interferon-response gene that 
is ubiquitously expressed by many cells in both the bone and hematopoietic 
compartments. Reports have shown that stromal cells that express Mx1 are responsible 
for the development and replenishment of osteoblasts in the bone marrow niche; lending 
support for my experiment design attempting to excise Tle4 within stromal cells in the 
bone marrow environment only129. Many different genes have been used to mark and 
identify various stages of osteoblast development, including Cola1, Osx and Nestin129,171. 
To accurately identify how Tle4 affects osteoblast differentiation and development, Tle4 
excision could be directed by other key markers of osteoblast development such as 
Cola1, Osx and Nestin. This would allow for a more directed Tle4 knockout that targets a 
specific stage of osteoblast development. If coupled with assays identifying concomitant 
changes in Runx2 and Wnt signaling, these experiments would provide greater insight to 
how Tle4 status may or may not affect osteoblast development in an osteoblast 
differentiation stage-specific manner; and consequently, provide additional information 
that could reconcile the seemingly disparate results found in the T4F cre MAR assay 
results. 
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CHAPTER FIVE: CONCLUDING REMARKS 
Summary of results 
 The work in this dissertation provides insight into the role of TLE4 as a tumor 
suppressor in t(8;21) AML and a master regulator of hematopoietic and bone 
development. Using Kasumi-1 cells, I have found TLE4 knockdown conferred increased 
cell proliferation, measured by tracking cell growth and measuring cell cycle. 
Concomitantly, T4KD decreased dead populations, blunted ATRA-induced 
differentiation potential, and increased cytarabine resistance of Kasumi-1 cells. RNAseq 
analysis using shTLE4-treated Kasumi-1 cells revealed enrichment of immune system 
and cytokine signaling pathways. Consistent with prior work describing the relationship 
between AML1-ETO and COX-dependent Wnt signaling14, I have found that Wnt 
signaling mediates pro-leukemic effects due to TLE4 knockdown and leads to 
upregulation of an inflammatory signature. Additionally, these effects were stunted by 
pharmacologic inhibition of β-Catenin/TCF and COX activity. These novel findings not 
only provide additional evidence for the oncogenic role of inflammation and Wnt 
signaling in leukemia, but also further elucidate a mechanistic explanation for the pro-
leukemic role loss of TLE4 plays in t(8;21) del(9q) myeloid leukemia. 
 By exploiting a Tle4 null mouse model, we have uncovered a new role of Tle4 in 
regulating bone and hematopoietic development. In addition to stem cell-intrinsic 
hematopoietic defects, T4KO mice exhibit severe deficiencies in bone mineralization and 
skeletal development, which corresponds to a human case study of congenital vertebral 
and bone deficiencies associated with a missense TLE4 mutation161. My findings suggest 
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that a contributing factor underlying these bone abnormalities is defective osteoblast 
function and maintenance due to Tle4 loss. Using T4KO stromal cultures and ST2D cells 
cultured in osteogenic media, I have found alkaline phosphatase activity and gene 
expression – in addition to expression of other osteoblast-related genes, such as Oc and 
Runx2 – are sensitive to Tle4 levels. These abnormalities may contribute to an aberrant 
extrinsic regulation of hematopoiesis due to Tle4 loss, further suggested by increased 
TUNEL staining in T4KO bone marrow stroma and deficient maintenance of wild-type 
LSK cells by T4KO stromal cultures.  
 
Role of inflammation in pro-leukemic niche remodeling 
 While this dissertation has focused on inquiries regarding the role of Tle4 in the 
context of leukemia and normal mammalian development independently, these findings 
have potential intersections that may shed new light on our understanding of leukemia 
pathogenesis. It is now understood that leukemia does not grow very well ex vivo, and in 
fact depends on its localization in very specific microenvironments in the bone marrow41. 
Studies investigating carcinogenesis in various models of solid cancers have revealed the 
potential role of inflammation in creating a “pro-cancer environment.” 88-91 This has led 
to increased interest in understanding the role of inflammation in leukemia development, 
particularly in the context of LSC and their relationship to the HSC niche. Previous work 
has elucidated the importance of certain surface markers, such as CD44, E-selectin, 
HIF1α, and CXCR4, in LSC localization to the HSC niche and induction of niche 
remodeling41. While much research is currently pursued to understand the functional role 
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and mechanistic regulation of these factors, it is understood that they are important in 
creating a microenvironment that has a favorable bias towards LSC maintenance over 
normal HSC. LSCs have shown to have relative resistance to current AML chemotherapy 
agents, possibly due to their relative quiescence and subsequent ability to evade drugs 
that target DNA synthesis and active proliferation41,55. This allows for LSCs to survive 
chemotherapy and later develop relapse disease. Thus, increasing attention has been 
given towards understanding how LSCs interact with HSC niches and how the latter 
provides a protective environment for LSC survival. Prior work studying 
myeloproliferative neoplasia has revealed that inflammatory signals from leukemic cells 
are associated with myelofibrosis and restructuring of stromal and osteoblast-lineage cells 
to create a pro-leukemic HSC niche environment32. A more recent study has found that 
AML cells are also able to alter the transcriptome of bone marrow stromal cells through 
leukemic cell-stroma crosstalk and create an environment that selectively impairs the 
maintenance and viability of wild type HSC without affecting leukemic cells97. 
Moreover, a previous report has shown that activating mutations of b-Catenin in 
osteoblasts contributes to development of myelodysplastic syndrome and AML42,179.  
 Collectively, these reports provide evidence that pro-inflammatory changes in the 
bone marrow stromal cells and communication between resident cells in the HSC niche 
and leukemic cells contribute towards leukemogenesis. While my colleagues and I have 
found that loss of TLE4 impacts inflammatory gene expression in leukemic cells, 
additional studies are warranted to investigate whether this inflammation influences the 
HSC niche and how that may affect AML development and progression. Additional 
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preliminary experiments would include a query of whether loss of Tle4 induces gene 
expression and presence of inflammatory cytokines and mediators in the bone marrow. 
Recent work phenotyping Tle1 null mice by our laboratory has shown that loss of Tle1 is 
associated with increased baseline levels of inflammation in bone marrow and other 
tissue compartments due to increased NFkB signaling, which was shown to create a 
favorable environment for faster proliferation of engrafted melanoma cells96. While we 
do not know whether Tle1 and Tle4 share the same pro-inflammatory effects in bone 
marrow in vivo, the Tle1 null mouse phenotype warrants additional investigation of the 
relationship between inflammation and loss of Tle4. Interestingly, little is known about 
the cytogenetic and mutation status of bone marrow stromal cells in human AML patients 
in comparison to the leukemic cells themselves. Thus, it is indeed possible that, while 
Tle4 null leukemic cell transplants did not result in florid leukemia, the stromal effects 
are significant in perpetuating leukemogenesis. Moving forward, it would be interesting 
to see whether additional chromosomal abnormalities or gene mutations, especially those 
affecting TLE4, exist in the bone marrow stromal cells of human AML patients. Based on 
our findings, the laboratory has planned additional experiments aimed at looking at 
whether the addition of inflammatory signals or Wnt signaling, via inflammatory 
cytokines and rhWnt3a, respectively, can affect leukemia cell engraftment and stroma 
remodeling. We hope to achieve this preliminarily in an in vitro stromal co-culture model 
by using co-cultures of stromal and leukemia cells with Transwell inserts. This would 
allow for monitoring differences in leukemia cell migration as well as changes in stromal 
cell composition.  
		
123 
 Thus, our findings have significant implications on new directions and 
understanding of how Tle4 may be influencing t(8;21) del(9q) AML through not only 
leukemic cell-intrinsic effects but also through regulating crosstalk between leukemic 
cells and their microenvironment. With recent advancements in the field of 
immunotherapeutics and cancer immunology, understanding the role of inflammation in 
the context of leukemia and leukemic stem cell niches can contribute to how novel 
therapeutics can harness the role of immune responses in altering leukemogenesis. 
Additional insight into this relationship would greatly add to the field’s current efforts 
towards targeting the stem cell niche to eliminate long-term, residual leukemia stem cells 
and refractory disease.  
 
Future directions 
 While advances in chemotherapies have raised remission rates in AML patients, 
current treatments are unable to address substantial patient populations with refractory 
disease and five-year relapse risks of up to 44%152. Many of our current chemotherapy 
and combination therapies have significant sequelae and adverse effects which are not 
only toxic, but also render them inappropriate for certain patient populations. As such, 
there is an increasing need for the development of new drugs and strategies that are safer 
and wield higher efficacy. Work with other malignancies has elucidated the therapeutic 
potential of anti-inflammatory drugs. In particular, studies using familial adenomatous 
polyposis patients and mice with APC mutations have shown significant decreases the 
size and number of intestinal adenomas and polyps after treatment with celecoxib, a 
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COX2-selective inhibitor88. Epidemiologic evidence has shown an association between 
lifetime use of non-steroidal anti-inflammatory drugs with reduced risk of breast cancer 
among pre-menopausal women with sisters who have breast cancer89. Moreover, aspirin 
has been shown to have a synergistic effect on the ability of Metformin to induce 
apoptosis in breast cancer cells180. Thus, the experiments described in this dissertation 
provide additional insight into the potential applicability of anti-inflammatory drugs and 
COX inhibitors in the setting of leukemia therapeutics. The use of COX inhibitors in 
leukemia patients poses certain concerns especially due to the potential impairment of 
platelet function in patients who may be thrombocytopenic. However, the evidence 
implicating the role of inflammation in leukemogenesis warrants additional future studies 
that examine the use of COX2-specific inhibitors with less anti-platelet effects and 
further querying of additional downstream pathways or targets that may circumvent this 
potential side effect of COX inhibition treatment. These inhibitors could also be 
introduced after treatment and recovery of bone marrow function to reduce the rate of 
relapse. 
 These challenges emphasize a need for additional future studies examining the 
molecular and mechanistic relationship between TLE4 and AML1-ETO to fully 
understand how TLE4 functions as a tumor suppressor gene. Previously, members of our  
laboratory have been able to co-immunoprecipitate AML1-ETO and TLE4 after ectopic 
expression in 293T cells48. While interactions between TLE and the Runt homology 
domain AML/CBFa/RUNX family transcription factors has been previously described, it 
is thought that the t(8;21) occurs such that the interaction site between TLE and AML is 
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lost in the fusion AML1-ETO oncoprotein5,115,176. Identifying the exact interaction sites 
between TLE and AML1-ETO would provide further evidence for TLE-direct effects on 
AML1-ETO. My findings relating TLE4 knockdown with Wnt signaling and further 
suppression of AML1-ETO repressive targets argue for TLE4 exerting previously 
unrealized indirect effects on AML1-ETO function. ChIPseq experiments using 
antibodies for TLE4 and AML1-ETO would better characterize how TLE4 might interact 
with AML1-ETO as a transcriptional co-repressor. I hypothesize that successful ChIP-seq 
experiments will reveal co-localization of TLE4 recruitment sites and AML1-ETO 
binding sites at promoters of upregulated inflammatory genes identified by the RNAseq 
described here, as well as potentially genes related to cell cycle and proliferation targets 
that have been described as AML1-ETO repressive targets, such as CCND378. 
To further understand the physiologic role of Tle4 in normal mammalian 
development, our laboratory had developed a Tle4 null mouse model whose 
characterization studies revealed a novel role of Tle4 on hematopoiesis and bone 
development. These two processes are intimately related as normal regulation of 
hematopoiesis depends on development and maintenance of healthy bone. Our studies 
here provide a premise for investigating the role of Tle4 on osteoblast function and 
viability. However, the assays and mouse models used are not able to precisely isolate 
Tle4 knockout effects on osteoblast development. While previous studies have shown 
Mx1-expressing resident stromal cells are responsible for new osteoblast and bone 
growth129, other groups have successfully described various stages of osteoblast 
development by exploiting other key osteoblast-specific transcription factors and 
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regulators, such as Cola1, Osx and Nestin129,171. Moving forward, our laboratory proposes 
developing transgenic mouse models with Tle4 excision targeted to specific stages of 
osteoblast development to better understand how Tle4 regulates osteoblast development. 
These experiments may provide further information that explains why loss of Tle4 is 
detrimental to bone growth.  
 Our laboratory is also interested in understanding how Tle4 affects 
osteoclastogenesis, another integral mediator of normal bone development and 
metabolism. Preliminary studies have shown that Tle4 null mice had increased osteoclast 
recruitment, as indicated by TRAP staining. Interestingly, inflammation in the bone has 
been associated with osteoclastogenesis and osteoclast activation181,182. Osteoclast 
activation depends on a variety of key regulatory processes, including the binding and 
activation of RANKL, a receptor activator of NFkB ligand. Han and colleagues have 
showed that activation of RANKL in osteoclast RAW264.7 cells induces COX2 
expression and prostaglandin production182. Furthermore, the same study showed 
celecoxib, a COX2-selective inhibitor, was able to block osteoclast differentiation of 
murine monocyte/macrophage cells, which was subsequently reversible with addition of 
prostaglandin E2182. Recent work by our laboratory has shown loss of Tle1 generates a 
hyper-inflammatory predisposition in mice, possibly due to increased NFkB activation96. 
While it is still unknown whether Tle1 and Tle4 share the same physiologic function in 
the context of NFkB-mediated inflammation, our results outlined in this dissertation 
support the notion that Tle4 plays a pivotal role in regulating inflammation and points 
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towards future studies examining whether Tle4 affects bone metabolism by modulating 
the relationship between inflammation and osteoclast activity. 
Greater understanding of how Tle4 affects bone development could reveal novel 
roles for Tle4-mediated regulation in various bone-related diseases, such as osteopenia 
and osteosarcoma. Osteopenia is a condition referring to abnormally low bone densities 
that is associated with various conditions and diseases resulting in frequent bone 
fractures25. Osteosarcoma is a bone malignancy where neoplastic cells proliferate and 
generate osteoid through aberrant increases in osteocalcin production25. Interestingly, the 
association found between a missense TLE4 mutation and a familial case of congenital 
vertebral abnormalities is the first descriptive evidence pointing towards the potential role 
of TLE4 in human bone development161. Given our observations of how loss of Tle4 
affects bone development in mice, it is clear that additional inquiries must be made to 
understand whether there is a causal relationship between mutant or loss of TLE4 and 
osteopenia as well as what molecular mechanisms are in play in the development of such 
phenotypes. Interestingly, osteosarcoma is a malignant cancer of the bone whose cells 
produces osteoid, the unmineralized bone matrix that serves as a precursor for bone25. 
While there have been no known associations or studies linking TLE4 and osteosarcoma, 
online data mining from Genesapiens show osteosarcoma cells tend to have less TLE4 
expression compared to normal bone tissue183. While the laboratory has future 
experiments planned to examine Osteocalcin protein levels, my preliminary data suggests 
that Oc expression levels are lower and osteoblast function may be deterred in Tle4 null 
mice. These findings lay the groundwork for a new series of investigations that may 
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unveil a novel role for Tle4 in osteosarcoma and provide additional insight to therapeutic 
strategies. 
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